# USE CASE 23: HEALTH TECHNOLOGY ASSESSMENT (HTA) SUBMISSION STRATEGY

**UC_MA_009: Health Technology Assessment (HTA) Submission Strategy**

**Version**: 2.1  
**Last Updated**: October 2025  
**Status**: Production-Ready âœ…  
**Prompt ID Range**: `VALUE_JUSTIFY_HTA_*`  
**Complexity Level**: EXPERT  
**Estimated Completion Time**: 40-60 hours (preparation) + 6-12 months (submission cycle)

---

## ðŸ“‹ TABLE OF CONTENTS

1. [Use Case Overview](#1-use-case-overview)
2. [Problem Statement & Context](#2-problem-statement--context)
3. [Persona Definitions](#3-persona-definitions)
4. [Prompt Engineering Strategy](#4-prompt-engineering-strategy)
5. [Step-by-Step Workflow](#5-step-by-step-workflow)
6. [Quality Assurance & Validation](#6-quality-assurance--validation)
7. [Integration with Other Use Cases](#7-integration-with-other-use-cases)
8. [Industry Benchmarks & Success Metrics](#8-industry-benchmarks--success-metrics)
9. [Appendices](#9-appendices)

---

## 1. USE CASE OVERVIEW

### 1.1 Use Case Summary

**Primary Objective**: Develop comprehensive Health Technology Assessment (HTA) submission packages for major global HTA bodies (NICE, ICER, CADTH, IQWiG/G-BA, HAS, PBAC) to secure favorable reimbursement recommendations and market access.

**Target Outcome**: Approved HTA submissions that result in positive reimbursement recommendations, enabling market access and optimal pricing in key global markets.

**Business Impact**:
- **Market Access**: 70-90% of global pharmaceutical markets require HTA evaluation
- **Revenue**: HTA outcomes directly impact pricing and reimbursement, affecting $5-50M+ in annual revenue per product per market
- **Timeline**: HTA preparation and approval process typically 6-24 months depending on jurisdiction
- **Strategic**: Positive HTA decisions create precedent for other markets and payers

### 1.2 When to Use This Use Case

**Mandatory Scenarios**:
âœ… Launching new pharmaceutical product in markets with mandatory HTA (UK, Germany, France, Canada, Australia)  
âœ… Seeking premium pricing above standard reimbursement levels  
âœ… Novel mechanism of action or first-in-class therapy requiring value demonstration  
âœ… High-cost specialty medications (>$10,000/patient/year)  
âœ… Digital therapeutics seeking national reimbursement pathways  

**Strategic Scenarios**:
âœ… Building evidence base to support US payer negotiations (ICER review)  
âœ… Responding to HTA body review or reassessment  
âœ… Lifecycle management: new indication, new formulation, or expanded population  
âœ… Defending against generic/biosimilar competition through value demonstration  
âœ… Supporting global pricing strategy with HTA-anchored reference prices  

**NOT Appropriate For**:
âŒ Generic products with established comparators (limited differential value)  
âŒ Over-the-counter (OTC) products without prescription pathway  
âŒ Markets without formal HTA processes  
âŒ Products with insufficient clinical evidence (Phase I/II only)  
âŒ When clinical evidence clearly shows non-inferiority with higher cost  

### 1.3 Primary Users

**Primary Users**:
1. **Market Access Directors**: Overall HTA strategy, cross-functional coordination, HTA body engagement
2. **Health Economics & Outcomes Research (HEOR) Analysts**: Economic modeling, evidence synthesis, technical dossier preparation
3. **Medical Affairs**: Clinical evidence synthesis, clinical expert engagement, endpoint justification

**Secondary Users**:
4. **Regulatory Affairs**: Coordinate HTA and regulatory timelines, ensure consistency in evidence claims
5. **Global Pricing & Reimbursement**: Use HTA outcomes to inform pricing strategy across markets
6. **Commercial Leadership**: Understand market access timelines and risks for launch planning
7. **External Consultants**: HTA specialists, health economists, evidence synthesis experts

### 1.4 Key Deliverables

Upon completion of UC_MA_009, you will have:

**Core HTA Submission Packages** (by jurisdiction):
- âœ… **NICE Technology Appraisal Submission** (UK): Company evidence submission, economic model, clinical effectiveness review
- âœ… **ICER Evidence Report** (US): Evidence dossier, economic analysis, patient/clinician perspectives
- âœ… **CADTH Common Drug Review (CDR)** (Canada): Clinical review, pharmacoeconomic evaluation, budget impact analysis
- âœ… **IQWiG/G-BA Early Benefit Assessment** (Germany): Dossier Modules 1-4, comparative benefit evaluation
- âœ… **HAS (Haute AutoritÃ© de SantÃ©) Dossier** (France): ASMR rating justification, economic evaluation, real-world evidence
- âœ… **PBAC Submission** (Australia): Clinical evaluation, economic evaluation, financial implications

**Supporting Evidence Documents**:
- âœ… **Systematic Literature Review (SLR)**: PRISMA-compliant SLR with evidence synthesis
- âœ… **Network Meta-Analysis (NMA)**: Comparative effectiveness vs. all relevant comparators
- âœ… **Cost-Effectiveness Model**: Economic model following jurisdiction-specific methods guidelines
- âœ… **Budget Impact Model**: 3-5 year financial impact analysis
- âœ… **Clinical Expert Validation**: Letters of support, advisory board summaries
- âœ… **Patient Input Submissions**: Patient advocacy group testimonials, patient experience data

**Process Documentation**:
- âœ… **HTA Submission Strategy Document**: Overall approach, timelines, risk mitigation
- âœ… **Evidence Gap Analysis**: Identification of evidence weaknesses and mitigation plans
- âœ… **HTA Body Engagement Log**: Meeting notes, clarification questions, responses
- âœ… **Cross-Market Consistency Plan**: Ensure consistent claims across HTA submissions

---

## 2. PROBLEM STATEMENT & CONTEXT

### 2.1 The Global HTA Landscape

Health Technology Assessment has evolved from a niche requirement in select European markets to a **global gatekeeper** for pharmaceutical market access:

**Historical Evolution**:
- **1990s**: NICE established in UK (1999) as first national HTA body
- **2000s**: Proliferation of HTA across Europe (Germany, France, Sweden, Netherlands)
- **2010s**: HTA expansion to Canada, Australia, Asia-Pacific; ICER emerges in US
- **2020s**: Digital health HTA pathways (NICE DHT, German DiGA), real-world evidence integration

**Current State (2025)**:
- **70+ countries** have some form of HTA process
- **Mandatory** in most European countries, Canada, Australia for reimbursement
- **Influential** in US despite lack of federal mandate (ICER affects payer decisions)
- **Evolving** for digital therapeutics, cell/gene therapies, diagnostics, medical devices

### 2.2 Why HTA Submissions Are Critical

HTA evaluations serve three critical functions:

**1. Regulatory Gatekeeper to Reimbursement**
- In most countries, positive HTA outcome is **mandatory** for national reimbursement
- Negative HTA decision can result in:
  - Complete denial of reimbursement
  - Restricted access (limited to subpopulations)
  - Unfavorable pricing (mandated price cuts)
  - Delayed market access (12-24+ months for reassessment)

**2. Pricing Leverage and Negotiations**
- HTA outcome directly influences:
  - **Maximum reimbursed price**: Ceiling on what payers will cover
  - **Reference pricing**: Other markets use HTA decisions as benchmarks
  - **Managed entry agreements**: Risk-sharing, outcomes-based contracts
  - **Formulary positioning**: Preferred vs. restricted access

**3. Scientific Credibility and Market Precedent**
- Positive HTA creates:
  - **Clinical evidence validation**: Independent review confirms therapeutic value
  - **Competitive differentiation**: Superior HTA outcome vs. competitors
  - **Global cascading effect**: Other HTA bodies reference prior assessments
  - **Payer confidence**: Commercial payers more willing to cover

### 2.3 Major HTA Bodies: Requirements & Methods

#### A. NICE (National Institute for Health and Care Excellence) - United Kingdom

**Overview**:
- Established: 1999
- Scope: Technology Appraisals (TA), Highly Specialized Technologies (HST), Digital Health Technologies (DHT)
- Decision criteria: Cost per QALY gained, end-of-life considerations, innovation

**Key Requirements**:
- **Cost-effectiveness threshold**: Â£20,000-30,000 per QALY (standard); Â£50,000-100,000 per QALY (end-of-life, rare diseases)
- **Economic model**: Submitted by company, critiqued by Evidence Review Group (ERG)
- **Evidence standards**: Prefer RCT data; accept indirect comparisons if no head-to-head trials
- **Timeline**: 9-12 months from submission to final guidance
- **Outcome**: Recommended, Optimized (restricted), Not Recommended

**Critical Success Factors**:
- Robust economic model that withstands ERG critique
- Comprehensive network meta-analysis covering all comparators
- Clear demonstration of QALY gains (typically need >0.3 QALY gain)
- Proactive engagement with ERG during appraisal process
- Strong patient and clinical expert input

**Common Pitfalls**:
- Inadequate justification of model assumptions (ERG will critique heavily)
- Failure to include all relevant comparators in clinical effectiveness review
- Optimistic extrapolation of trial data without validation
- Insufficient scenario analyses to address uncertainty

#### B. ICER (Institute for Clinical and Economic Review) - United States

**Overview**:
- Established: 2006 (modern iteration)
- Scope: High-cost, high-impact drugs and interventions
- Decision criteria: Cost per QALY, budget impact, long-term value for money

**Key Requirements**:
- **Cost-effectiveness threshold**: $100,000-150,000 per QALY (informal US standard)
- **Budget impact threshold**: $915M per year (trigger for affordability concern)
- **Evidence standards**: Systematic review, network meta-analysis, long-term outcomes modeling
- **Timeline**: 6-9 months from scoping to final report
- **Outcome**: Ratings for "long-term value for money" and "short-term affordability"

**Critical Success Factors**:
- Engagement in scoping process to influence scope and comparators
- Comprehensive evidence submission during public comment period
- Strong clinical expert and patient advocacy support
- Realistic pricing that achieves favorable cost-effectiveness
- Demonstration of addressing unmet need in high-burden disease

**Common Pitfalls**:
- Late engagement (after scope is finalized)
- Failure to address budget impact concerns (ICER weighs this heavily)
- Insufficient patient perspective data
- Over-reliance on surrogate endpoints without demonstration of long-term benefit

#### C. CADTH (Canadian Agency for Drugs and Technologies in Health) - Canada

**Overview**:
- Established: 1989 (as CCOHTA)
- Scope: Common Drug Review (CDR), pan-Canadian Oncology Drug Review (pCODR)
- Decision criteria: Clinical effectiveness, cost-effectiveness, adoption feasibility

**Key Requirements**:
- **Cost-effectiveness**: No fixed threshold, but typically expect <$50,000 CAD/QALY
- **Economic evaluation**: Company-submitted model plus CADTH reanalysis
- **Evidence standards**: RCT data strongly preferred; strict indirect comparison criteria
- **Timeline**: 6-10 months from submission to recommendation
- **Outcome**: Reimburse, Reimburse with Criteria, Do Not Reimburse

**Critical Success Factors**:
- High-quality clinical evidence (pivotal RCT with Canadian relevance)
- Conservative economic model (CADTH reanalysis is typically more conservative)
- Clear budget impact justification
- Alignment with Canadian clinical guidelines
- Provincial engagement (CADTH is advisory; provinces make final decisions)

**Common Pitfalls**:
- Overly optimistic economic assumptions (CADTH will revise downward)
- Lack of Canadian-specific data (generalizability concerns)
- Insufficient safety data in target population
- Inadequate consideration of implementation barriers

#### D. IQWiG / G-BA (Germany)

**Overview**:
- IQWiG: Institute for Quality and Efficiency in Health Care (conducts assessment)
- G-BA: Federal Joint Committee (makes reimbursement decisions)
- Established: 2004 (IQWiG), 2004 (G-BA AMNOG process)
- Scope: Early benefit assessment for new drugs under AMNOG framework

**Key Requirements**:
- **Benefit assessment**: Comparative benefit vs. "appropriate comparator therapy" (ACT)
- **Added benefit categories**: Major, considerable, minor, non-quantifiable, no added benefit
- **Evidence standards**: Patient-relevant endpoints (mortality, morbidity, QoL, safety); surrogate endpoints generally not accepted
- **Timeline**: 6 months for assessment + negotiation phase
- **Outcome**: Added benefit rating determines price negotiation leverage

**Critical Success Factors**:
- Strong comparative data vs. the specified ACT (ideally head-to-head RCT)
- Patient-relevant endpoints that show clinically meaningful differences
- Subgroup analyses for relevant patient populations
- High-quality patient-reported outcomes data
- Alignment with German clinical practice

**Common Pitfalls**:
- Reliance on surrogate endpoints (IQWiG largely rejects these)
- Indirect comparisons with high uncertainty
- Lack of data in key subgroups
- Failure to address IQWiG's methodological preferences (e.g., responder analyses)

#### E. HAS (Haute AutoritÃ© de SantÃ©) - France

**Overview**:
- Established: 2004
- Scope: Medical Service Rendered (SMR) rating, Improvement in Medical Service Rendered (ASMR)
- Decision criteria: Clinical benefit, public health impact, cost-effectiveness

**Key Requirements**:
- **ASMR rating**: I (major), II (important), III (moderate), IV (minor), V (no improvement)
- **SMR rating**: Determines whether drug is reimbursed and at what rate
- **Economic evaluation**: Required for drugs seeking price premium
- **Timeline**: 6-9 months from submission to decision
- **Outcome**: ASMR and SMR ratings determine reimbursement and price

**Critical Success Factors**:
- Clear articulation of clinical added value vs. existing treatments
- Strong real-world evidence demonstrating effectiveness in French clinical practice
- Alignment with French clinical guidelines
- Demonstration of impact on public health priorities
- Patient advocacy support

**Common Pitfalls**:
- Insufficient real-world evidence (HAS increasingly requires this)
- Weak comparator choice (not aligned with French practice)
- Lack of French-specific subgroup data
- Over-claiming clinical benefit that evidence doesn't support

#### F. PBAC (Pharmaceutical Benefits Advisory Committee) - Australia

**Overview**:
- Established: 1953
- Scope: Pharmaceutical Benefits Scheme (PBS) listing recommendations
- Decision criteria: Cost-effectiveness, clinical need, budget impact, equity

**Key Requirements**:
- **Cost-effectiveness**: Typically expect <$50,000 AUD/QALY for standard treatments
- **Economic evaluation**: Choice of superiority, non-inferiority, or cost-minimization claims
- **Evidence standards**: Strong preference for RCT data; strict indirect comparison standards
- **Timeline**: 6-12 months (can be longer if rejected and resubmitted)
- **Outcome**: Recommend for listing, Reject, Defer

**Critical Success Factors**:
- Selection of appropriate economic evaluation type (superiority, non-inferiority, cost-minimization)
- Conservative modeling assumptions (PBAC is highly conservative)
- Clear articulation of place in therapy
- Demonstrated clinical need and unmet need
- Managed entry agreement proposal if cost-effectiveness borderline

**Common Pitfalls**:
- Claiming superiority without sufficient evidence (should claim non-inferiority if uncertain)
- Optimistic model assumptions (PBAC will reject)
- Insufficient Australian-specific data
- Lack of engagement with clinical experts to validate comparator and place in therapy

### 2.4 Common Challenges Across HTA Submissions

#### Challenge 1: Evidence Gaps
**Problem**: Clinical trial design may not align with HTA evidence requirements
- Trial compared to placebo, but HTA requires comparison to standard of care
- Short trial duration, but HTA requires long-term outcomes projection
- Surrogate endpoints used, but HTA requires patient-relevant outcomes

**Impact**: 
- Increased reliance on indirect comparisons (less credible)
- Longer model extrapolation (higher uncertainty)
- Potential for negative HTA decision

**Mitigation Strategies**:
- Early HTA engagement (pre-Phase III) to align trial design
- Real-world evidence generation to complement RCT data
- Multiple scenario analyses to address uncertainty
- Expert elicitation to inform long-term projections

#### Challenge 2: Cross-Market Inconsistency
**Problem**: Different HTA bodies have conflicting requirements
- NICE accepts cost per QALY; IQWiG focuses on patient-relevant benefit (doesn't use QALYs)
- ICER emphasizes budget impact; NICE focuses more on cost-effectiveness
- CADTH requires Canadian data; PBAC requires Australian data

**Impact**:
- Resource-intensive: Cannot use single dossier across markets
- Risk of inconsistent claims leading to HTA body concerns
- Timing challenges: Staggered submissions delay global launch

**Mitigation Strategies**:
- Develop core evidence platform that can be adapted per market
- Consistent clinical narrative with market-specific economic framing
- Parallel submission strategy where possible
- Cross-market working group to ensure consistency

#### Challenge 3: Uncertain or Unfavorable Cost-Effectiveness
**Problem**: Product doesn't meet HTA body's cost-effectiveness threshold at desired price
- ICER >$150,000/QALY (above US informal threshold)
- ICER >Â£30,000/QALY (above NICE standard threshold)
- Budget impact >$915M/year (triggers ICER affordability concern)

**Impact**:
- Negative HTA recommendation
- Pressure to reduce price
- Restricted access recommendations

**Mitigation Strategies**:
- Value-based pricing: Align price to achieve acceptable ICER
- Managed entry agreements: Outcomes-based contracts, cost-capping
- Subpopulation strategies: Seek approval in highest-value population first
- Innovation arguments: End-of-life, rare disease, significant innovation

#### Challenge 4: Timing and Coordination
**Problem**: HTA process timing misaligned with business needs
- Regulatory approval delayed â†’ HTA submission delayed
- HTA process duration (6-24 months) delays revenue
- Sequential submissions across markets extend time to global access

**Impact**:
- Delayed revenue realization ($5-20M+ per quarter delay)
- Competitive disadvantage if competitor launches first
- Increased cost of capital

**Mitigation Strategies**:
- Parallel regulatory-HTA pathways (scientific advice meetings)
- Early HTA submissions (pre-approval where allowed)
- Prioritize high-value markets first
- Leverage fast-track pathways where available

### 2.5 HTA Submission Success Rates & Benchmarks

| HTA Body | Submission Success Rate | Average Timeline | Key Success Factor |
|----------|------------------------|------------------|-------------------|
| **NICE (UK)** | 65-70% positive recommendation first time | 9-12 months | Robust economic model, comprehensive NMA |
| **ICER (US)** | 45-55% favorable value rating | 6-9 months | Strong patient advocacy, addressing budget impact |
| **CADTH (Canada)** | 55-65% positive recommendation | 6-10 months | High-quality RCT, conservative economic model |
| **IQWiG/G-BA (Germany)** | 50-60% "added benefit" rating | 6 months assessment + negotiation | Patient-relevant endpoints, direct comparisons |
| **HAS (France)** | 60-70% ASMR III or better | 6-9 months | Real-world evidence, public health impact |
| **PBAC (Australia)** | 50-60% recommended for listing | 6-12 months | Conservative claims, Australian data |

**Industry Benchmarks**:
- **Average cost per HTA submission**: $150,000-500,000 (varies by complexity and external consultant use)
- **Internal resource hours**: 500-1500 hours per submission (HEOR, medical affairs, market access)
- **External consultant costs**: $50,000-300,000 per submission (health economists, evidence synthesis experts)
- **Revenue at stake per market**: $5-50M+ annual revenue (varies by indication and market size)

### 2.6 Value Proposition of This Use Case

**Direct Benefits**:
1. **Market Access**: 50-70% higher likelihood of positive HTA outcome (systematic, evidence-based submissions)
2. **Revenue Protection**: $5-50M+ annual revenue per market secured through positive HTA
3. **Pricing Leverage**: 15-30% higher reimbursed price achievable with strong HTA value demonstration
4. **Timeline Optimization**: 3-6 months faster HTA approval (vs. ad-hoc, reactive approach)
5. **Cost Savings**: 40-60% reduction in external consultant costs (internal capability building)

**Indirect Benefits**:
1. **Global Precedent**: Positive HTA in key market (e.g., NICE, ICER) influences other markets
2. **Competitive Advantage**: Superior HTA outcomes vs. competitors strengthen market position
3. **Payer Confidence**: HTA approval increases US commercial payer willingness to cover
4. **Clinical Credibility**: Independent HTA validation enhances clinical community confidence
5. **Portfolio Optimization**: HTA insights inform future product development and evidence generation

### 2.7 Integration with Other Use Cases

UC_MA_009 depends on and informs several other use cases in the Life Sciences Prompt Library:

**Dependencies** (must complete first or in parallel):
- **UC_CLIN_002** (Clinical Trial Design): Trial design must anticipate HTA evidence requirements
- **UC_CLIN_004** (DTx Clinical Endpoint Selection): Endpoints must be HTA-relevant (patient-reported, meaningful)
- **UC_MA_002** (Health Economics Modeling): CEA and BIM are core components of HTA submission
- **UC_MA_001** (Payer Value Dossier): Many elements overlap with HTA submissions
- **UC_MEDICAL_002** (Systematic Literature Review): SLR is foundation of HTA evidence synthesis

**Informed by UC_MA_009**:
- **UC_MA_003** (Pricing Strategy): HTA outcomes inform global pricing strategy
- **UC_MA_004** (Formulary Positioning): US payers consider ICER ratings in formulary decisions
- **UC_COMM_001** (KOL Engagement): HTA expert engagement informs clinical narrative
- **UC_REG_005** (Real-World Evidence Strategy): HTA feedback identifies RWE needs for reassessment

---

## 3. PERSONA DEFINITIONS

This use case requires collaboration across six key personas, each bringing critical expertise to ensure rigorous, defensible HTA submissions.

### P21_HEOR - Health Economics & Outcomes Research Specialist

**Role**: Lead health economist responsible for economic model development, evidence synthesis, and HTA technical writing.

**Expertise**:
- Cost-effectiveness modeling (Markov models, discrete event simulation, partitioned survival)
- Network meta-analysis and indirect treatment comparisons
- Budget impact modeling
- HTA methods guidelines (NICE, ICER, CADTH, IQWiG)
- Systematic literature reviews (PRISMA standards)
- Statistical methods for comparative effectiveness

**Key Responsibilities in UC_MA_009**:
- Develop HTA-specific economic models per jurisdiction requirements
- Conduct systematic literature reviews and network meta-analyses
- Prepare technical HTA dossier sections (clinical effectiveness, economic evaluation)
- Respond to HTA body questions and critiques
- Validate model assumptions with clinical experts
- Ensure compliance with HTA methods guidelines

**Typical Background**:
- PhD or Master's in Health Economics, Epidemiology, or Statistics
- 5-10+ years HEOR experience with HTA submission track record
- ISPOR member, published in peer-reviewed journals
- Experience with HTA body engagement (NICE ERG, ICER, CADTH)

**Success Criteria**:
- Economic model withstands HTA body critique (minimal revisions required)
- Evidence synthesis comprehensive and defensible
- Technical accuracy: 100% compliance with methods guidelines
- Responsiveness: <5 day turnaround for HTA clarification questions

---

### P22_MADIRECT - Market Access Director

**Role**: Overall HTA strategy lead, cross-functional coordinator, HTA body relationship manager.

**Expertise**:
- HTA strategy and submission planning
- Stakeholder engagement (HTA bodies, payers, clinical experts)
- Reimbursement landscape and market access dynamics
- Cross-functional team leadership
- Risk assessment and mitigation
- Negotiation and advocacy

**Key Responsibilities in UC_MA_009**:
- Develop overall HTA submission strategy and timelines
- Coordinate cross-functional HTA team (HEOR, medical, regulatory, legal)
- Engage with HTA bodies (scientific advice meetings, clarification responses)
- Manage external consultants (HTA specialists, evidence synthesis firms)
- Monitor HTA process and adapt strategy as needed
- Negotiate managed entry agreements if required

**Typical Background**:
- Advanced degree (MBA, Master's in Public Health, PharmD)
- 8-15+ years market access experience with HTA leadership
- Strong understanding of global reimbursement landscape
- Proven track record of successful HTA submissions

**Success Criteria**:
- Positive HTA outcome (recommended for reimbursement)
- On-time submission (no delays due to poor coordination)
- Effective HTA body engagement (proactive, responsive)
- Managed entry agreement negotiated successfully (if needed)

---

### P23_MEDAFFAIRS - Medical Affairs Director

**Role**: Clinical evidence strategy lead, clinical expert engagement, clinical narrative development.

**Expertise**:
- Clinical trial interpretation and data analysis
- Clinical practice guidelines and standard of care
- Key opinion leader (KOL) network and engagement
- Patient-reported outcomes and quality of life measures
- Safety profile and risk-benefit assessment
- Medical writing and evidence communication

**Key Responsibilities in UC_MA_009**:
- Develop clinical narrative for HTA submission
- Engage clinical experts to validate comparators and clinical claims
- Coordinate patient advocacy input for HTA submissions
- Respond to HTA clinical questions and critiques
- Validate clinical assumptions in economic model
- Prepare clinical expert statements and testimonials

**Typical Background**:
- MD, PharmD, or PhD with clinical research experience
- 8-15+ years in medical affairs or clinical development
- Strong clinical KOL network
- Experience with HTA clinical evidence requirements

**Success Criteria**:
- Clinical narrative accepted by HTA body with minimal questions
- Strong clinical expert support (letters, testimonials, advisory boards)
- Patient input submissions demonstrate real-world value
- Clinical assumptions in economic model validated and defensible

---

### P24_REGULATORY - Regulatory Affairs Manager

**Role**: Ensure HTA submissions align with regulatory approvals, manage regulatory-HTA interface.

**Expertise**:
- Regulatory approval pathways (FDA, EMA)
- Clinical trial design and regulatory requirements
- Product labeling and claims
- Regulatory-HTA coordination and timing
- Post-market commitments and evidence generation

**Key Responsibilities in UC_MA_009**:
- Ensure HTA claims consistent with regulatory approval and labeling
- Coordinate HTA submission timelines with regulatory milestones
- Identify regulatory-HTA evidence gaps
- Support HTA scientific advice meetings (regulatory perspective)
- Ensure post-market evidence commitments align with HTA needs

**Typical Background**:
- RAC (Regulatory Affairs Certification) or equivalent
- 5-10+ years regulatory affairs experience
- Experience coordinating regulatory and HTA processes
- Understanding of evidence requirements for both regulatory and HTA

**Success Criteria**:
- No discrepancies between HTA submission and regulatory approval
- HTA submission timeline aligned with regulatory milestones
- Regulatory-HTA evidence gaps identified early and addressed
- Post-market evidence plans support potential HTA reassessment

---

### P25_PRICING - Global Pricing & Reimbursement Lead

**Role**: Inform HTA pricing strategy, negotiate pricing based on HTA outcomes.

**Expertise**:
- Global pricing strategy and international reference pricing (IRP)
- Reimbursement negotiations and managed entry agreements
- Budget impact and affordability considerations
- Pricing corridor analysis (balancing revenue and access)
- Value-based pricing and outcomes-based contracts

**Key Responsibilities in UC_MA_009**:
- Inform HTA pricing scenarios and sensitivity analyses
- Assess impact of HTA outcomes on global pricing strategy
- Negotiate managed entry agreements if HTA outcome requires
- Model revenue impact of different HTA pricing scenarios
- Coordinate pricing across markets to manage IRP impact

**Typical Background**:
- Advanced degree (MBA, Economics, Pharmacy)
- 8-15+ years global pricing and reimbursement experience
- Understanding of HTA's impact on pricing and market access
- Experience negotiating value-based contracts and MEAs

**Success Criteria**:
- HTA pricing strategy maximizes revenue while securing access
- Managed entry agreements negotiated successfully (if needed)
- Global pricing strategy accounts for HTA outcomes
- Revenue targets achieved in HTA markets

---

### P26_PATIENT_ADVOCACY - Patient Advocacy & Engagement Lead

**Role**: Coordinate patient input for HTA submissions, gather patient perspective data.

**Expertise**:
- Patient advocacy group relationships
- Patient-reported outcomes (PROs) and patient experience
- Patient input submission preparation
- Qualitative research methods (interviews, focus groups)
- Patient engagement strategy

**Key Responsibilities in UC_MA_009**:
- Coordinate patient advocacy group input for HTA submissions
- Gather patient experience data (testimonials, surveys, interviews)
- Prepare patient input submissions for HTA bodies
- Ensure patient perspective integrated in clinical narrative
- Engage patient advocates for HTA public consultations

**Typical Background**:
- Background in patient advocacy, nursing, social work, or public health
- 5-10+ years patient engagement experience
- Strong patient advocacy group network
- Understanding of HTA patient input requirements

**Success Criteria**:
- Patient input submissions submitted on time to HTA bodies
- Strong patient advocacy support for HTA assessment
- Patient perspective integrated throughout HTA dossier
- Patient testimonials and experience data compelling and credible

---

## 4. PROMPT ENGINEERING STRATEGY

### 4.1 Prompt Architecture for HTA Submissions

HTA submissions require multi-layered prompt engineering that combines:

**Layer 1: Jurisdiction-Specific Templates**
- Separate prompt templates for each HTA body (NICE, ICER, CADTH, etc.)
- Incorporate jurisdiction-specific methods guidelines and evidence standards
- Adapt structure to match HTA body's submission template

**Layer 2: Evidence Type Modules**
- Systematic literature review prompts (PRISMA-compliant)
- Network meta-analysis prompts (indirect treatment comparison)
- Cost-effectiveness model prompts (CEA structure and assumptions)
- Budget impact model prompts (financial projections)
- Clinical effectiveness synthesis prompts

**Layer 3: Cross-Market Consistency Layer**
- Core clinical narrative that remains consistent across markets
- Flagging system for inconsistent claims across submissions
- Governance to ensure scientific integrity across markets

**Layer 4: Quality Assurance Layer**
- Technical validation (methods compliance)
- Clinical validation (clinical plausibility)
- Legal review (regulatory consistency, off-label claims)
- Cross-functional review (HEOR, medical, market access, regulatory)

### 4.2 Prompt Pattern: NICE Technology Appraisal

**Primary Prompt ID**: `VALUE_JUSTIFY_NICE_SUBMISSION_EXPERT_v2.9`

**Pattern Type**: Structured Evidence Synthesis + Economic Modeling

**Template Structure**:
```yaml
PROMPT: NICE Technology Appraisal Submission Development

ROLE:
You are a Senior Health Economist with 15+ years experience preparing NICE Technology Appraisal submissions. You are an expert in NICE methods guidelines, cost-effectiveness modeling, and Evidence Review Group (ERG) expectations.

CONTEXT:
- HTA Body: NICE (National Institute for Health and Care Excellence), UK
- Submission Type: Single Technology Appraisal (STA)
- Methods Reference: NICE Methods Guide (2022), NICE DSU Technical Support Documents
- Cost-Effectiveness Threshold: Â£20,000-30,000/QALY (standard), Â£50,000-100,000/QALY (end-of-life)
- Timeline: 9-12 months from submission to final guidance

INPUT VARIABLES:
- Product Name: {product_name}
- Indication: {indication}
- Target Population: {population}
- Comparators: {comparators_list}
- Available Clinical Evidence: {clinical_evidence_summary}
- Regulatory Status: {regulatory_status}
- Expected Appraisal Timeline: {timeline}

TASK:
Develop a comprehensive NICE Technology Appraisal submission package including:
1. Company Evidence Submission (CES) - main dossier
2. Economic Model (Excel-based)
3. Clinical Effectiveness Systematic Review
4. Cost-Effectiveness Analysis
5. Budget Impact Analysis

OUTPUT STRUCTURE:
[Detailed NICE-specific structure following official template]

CRITICAL REQUIREMENTS:
- Strictly follow NICE Methods Guide (2022)
- Economic model must be ERG-ready (transparent, flexible, well-documented)
- All comparators in NICE scope must be included
- Network meta-analysis required if no head-to-head data
- Scenario analyses to address uncertainty
- Patient perspective integrated throughout

QUALITY CHECKS:
- [ ] Compliance with NICE methods guidelines: 100%
- [ ] All comparators addressed
- [ ] Model validation checklist completed
- [ ] Uncertainty adequately characterized
- [ ] ERG-readiness assessment passed
```

### 4.3 Prompt Pattern: ICER Evidence Report Response

**Primary Prompt ID**: `VALUE_JUSTIFY_ICER_SUBMISSION_ADVANCED_v2.7`

**Pattern Type**: Evidence Submission + Stakeholder Engagement

**Key Differences from NICE**:
- ICER is independent; company submits evidence but doesn't control process
- Focus on responding to ICER's draft evidence report
- Budget impact is weighted heavily (not just cost-effectiveness)
- Public comment process is critical engagement opportunity

### 4.4 Prompt Pattern: CADTH Common Drug Review

**Primary Prompt ID**: `VALUE_JUSTIFY_CADTH_SUBMISSION_ADVANCED_v2.6`

**Pattern Type**: Clinical + Economic Submission with Conservative Assumptions

**Key Differences**:
- CADTH will conduct independent reanalysis of company model
- Company should submit conservative model (CADTH typically revises assumptions downward)
- Canadian-specific data highly valued
- Strong alignment with Canadian clinical practice guidelines critical

### 4.5 Prompt Pattern: IQWiG/G-BA Early Benefit Assessment (Germany)

**Primary Prompt ID**: `VALUE_JUSTIFY_IQWIG_SUBMISSION_ADVANCED_v2.3`

**Pattern Type**: Comparative Benefit Assessment with Patient-Relevant Endpoints

**Key Differences**:
- Focus on comparative benefit vs. appropriate comparator therapy (ACT)
- Patient-relevant endpoints required (mortality, morbidity, QoL, safety)
- Surrogate endpoints generally NOT accepted
- No cost-effectiveness analysis in initial assessment (comes later in price negotiation)

### 4.6 Chain-of-Thought (CoT) for HTA Submissions

**HTA Submission CoT Pattern**:
```
Step 1: Jurisdiction Analysis
â†’ Which HTA body? What are their specific methods requirements?
â†’ What is the submission template and required sections?
â†’ What is the cost-effectiveness threshold and decision criteria?

Step 2: Evidence Gap Analysis
â†’ What clinical evidence is available (RCT, RWE, registries)?
â†’ Are there head-to-head trials vs. all comparators?
â†’ What evidence gaps exist, and how will we address them?

Step 3: Comparator Strategy
â†’ What are the appropriate comparators per HTA scope?
â†’ Is head-to-head data available, or do we need indirect comparisons?
â†’ What is the standard of care in this market?

Step 4: Economic Model Structure
â†’ What model type is appropriate (Markov, partitioned survival, DES)?
â†’ What is the time horizon (trial duration, lifetime, other)?
â†’ What health states are clinically relevant?

Step 5: Clinical Effectiveness Synthesis
â†’ Systematic literature review scope and strategy?
â†’ Network meta-analysis needed? Feasibility?
â†’ How to handle heterogeneity across trials?

Step 6: Cost-Effectiveness Analysis
â†’ What costs are included (drug, administration, monitoring, AEs)?
â†’ How are QALYs calculated (utility values, EQ-5D data)?
â†’ What is the expected ICER, and is it within threshold?

Step 7: Uncertainty and Sensitivity Analysis
â†’ One-way sensitivity analysis: Which parameters are most influential?
â†’ Scenario analysis: What if key assumptions change?
â†’ Probabilistic sensitivity analysis: What is probability of cost-effectiveness?

Step 8: Budget Impact
â†’ What is the eligible population size?
â†’ What is market uptake trajectory (years 1-5)?
â†’ What are the cost offsets (reduced hospitalizations, etc.)?

Step 9: Stakeholder Engagement
â†’ Clinical experts: Who can validate comparators and clinical assumptions?
â†’ Patient advocates: How to gather patient perspective?
â†’ HTA body: When to seek scientific advice?

Step 10: Quality Assurance
â†’ Technical validation: Methods compliance?
â†’ Clinical validation: Clinical plausibility?
â†’ Cross-functional review: HEOR, medical, regulatory, legal?
â†’ External review: Independent health economist validation?
```

### 4.7 Few-Shot Learning for HTA Submissions

**Example 1: NICE Submission for Novel Oncology Therapy**

*Input*: Novel checkpoint inhibitor for metastatic melanoma, no head-to-head vs. standard of care (ipilimumab + nivolumab), Phase III RCT vs. investigator's choice chemotherapy

*Output*: 
- Network meta-analysis connects novel agent â†’ chemotherapy â† ipilimumab + nivolumab
- Partitioned survival model with overall survival, progression-free survival, progressed disease health states
- EQ-5D utilities from trial mapped to health states
- Cost-effectiveness: Â£42,000/QALY (within end-of-life threshold Â£50K-100K)
- Sensitivity analysis shows ICER robust (Â£35K-Â£55K across scenarios)
- Budget impact: Â£45M over 5 years (852 patients)
- Recommendation: Approved (within end-of-life threshold, addresses unmet need)

**Example 2: ICER Review for Rare Disease Gene Therapy**

*Input*: Gene therapy for spinal muscular atrophy (SMA), one-time treatment, $2.1M list price, RCT shows dramatic motor function improvement

*Output*:
- Cost-effectiveness: $1.2M per QALY (well above $150K threshold)
- Budget impact: $2.8B over 5 years (triggers affordability concern)
- Long-term value: Rated "High" (transformative benefit for severe disease)
- Short-term affordability: Rated "Low" (substantial budget impact)
- Recommendation: Value-based pricing suggested ($900K-1.2M range), outcomes-based payment models to spread cost

**Example 3: CADTH Rejection Followed by Successful Resubmission**

*Input (Initial)*: Novel diabetes medication, non-inferiority to standard of care, priced 30% higher, CADTH rejects (not cost-effective)

*Output (Resubmission)*:
- Price reduction: 20% lower price
- Subpopulation focus: Restrict to patients with cardiovascular risk (higher benefit)
- Real-world evidence: Add Canadian registry data showing effectiveness in practice
- Managed entry agreement: Price-volume agreement to cap budget impact
- Recommendation: Approved with criteria (restricted population + managed entry agreement)

---

## 5. STEP-BY-STEP WORKFLOW

### PHASE 1: HTA STRATEGY & PLANNING (Weeks 1-4)

**Duration**: 4 weeks  
**Lead Personas**: P22_MADIRECT (Market Access Director), P21_HEOR (Health Economist)  
**Outcome**: HTA submission strategy document, evidence gap analysis, resource plan

---

#### STEP 1.1: HTA Landscape Assessment (Week 1)

**Objective**: Understand HTA requirements across target markets and prioritize submissions.

**Prompt ID**: `VALUE_JUSTIFY_HTA_LANDSCAPE_INTERMEDIATE_v2.1`

**Inputs**:
- Product profile (name, indication, MOA, clinical data)
- Target markets (countries/regions where launch planned)
- Expected regulatory approval timeline
- Competitive landscape (existing treatments, HTA outcomes for competitors)

**Instructions**:

```markdown
## HTA LANDSCAPE ASSESSMENT

You are a Market Access Director conducting an HTA landscape assessment for a new pharmaceutical product launch.

**Product Information**:
- Product Name: {product_name}
- Indication: {indication}
- Mechanism of Action: {moa}
- Phase III Trial Results: {trial_results_summary}
- Expected Regulatory Approval: {approval_date}
- Target List Price: {target_price}

**Target Markets**: {list_of_countries}

**Competitive Context**: {competitor_products_and_HTA_outcomes}

---

**TASK 1: HTA Body Identification**

For each target market, identify:
1. Which HTA body(ies) are relevant?
2. Is HTA mandatory or optional for reimbursement?
3. What is the typical timeline from submission to decision?
4. What are the decision criteria (cost-effectiveness threshold, clinical benefit, budget impact)?

**OUTPUT FORMAT**:
| Country | HTA Body | Mandatory? | Timeline | Cost-Effectiveness Threshold | Decision Criteria |
|---------|----------|------------|----------|------------------------------|-------------------|
| UK | NICE | Yes | 9-12 mo | Â£20K-30K/QALY (std), Â£50K-100K (EOL) | QALY gains, innovation |
| ... | ... | ... | ... | ... | ... |

---

**TASK 2: HTA Prioritization**

Prioritize HTA submissions based on:
- **Market size**: Revenue potential in that market
- **Strategic importance**: Reference pricing impact, precedent for other markets
- **Evidence readiness**: Availability of required evidence (clinical, economic)
- **Timeline urgency**: Time to revenue realization, competitive dynamics
- **Resource availability**: Internal/external resources to prepare submission

**Recommend**:
- Tier 1 (High Priority): Submit in {quarter/year}
- Tier 2 (Medium Priority): Submit in {quarter/year}
- Tier 3 (Lower Priority): Submit in {quarter/year} or defer

---

**TASK 3: Submission Timeline & Dependencies**

Create a high-level submission timeline considering:
- Regulatory approval timing (HTA submission typically after or parallel)
- HTA body submission windows and review cycles
- Dependencies between markets (e.g., wait for NICE outcome to inform ICER strategy)

**OUTPUT**: Gantt chart description with key milestones

---

**TASK 4: Resource Requirements**

Estimate resources required for HTA submissions:
- Internal FTEs (HEOR, medical affairs, market access, regulatory)
- External consultants (health economists, evidence synthesis, HTA specialists)
- Budget estimate per HTA submission
- Total budget for HTA program

**OUTPUT**: Resource plan and budget estimate
```

**Expected Output**:
- HTA landscape assessment report (10-15 pages)
- HTA prioritization matrix
- Submission timeline (Gantt chart)
- Resource plan and budget estimate

**Quality Check**:
- [ ] All target market HTA bodies identified
- [ ] Prioritization criteria clearly defined and applied
- [ ] Submission timeline realistic and accounts for dependencies
- [ ] Resource requirements quantified

---

#### STEP 1.2: Evidence Gap Analysis (Week 2)

**Objective**: Identify gaps between available evidence and HTA requirements, develop evidence generation plan.

**Prompt ID**: `VALUE_JUSTIFY_EVIDENCE_GAP_ADVANCED_v2.4`

**Inputs**:
- HTA landscape assessment from Step 1.1
- Available clinical evidence (RCT results, real-world evidence, patient-reported outcomes)
- Economic evidence (existing CEA, BIM if available)
- Comparator data (clinical trials, published literature)

**Instructions**:

```markdown
## HTA EVIDENCE GAP ANALYSIS

You are a Senior HEOR Analyst conducting an evidence gap analysis for HTA submissions.

**Available Evidence**:
- Phase III RCT: {trial_name}, N={sample_size}, comparator={comparator}, primary endpoint={endpoint}, result={result}
- Secondary endpoints: {list_secondary_endpoints_and_results}
- Safety data: {safety_summary}
- Quality of life data: {QoL_instrument}, results={results}
- Long-term follow-up: {available_or_planned}
- Real-world evidence: {RWE_studies_if_available}

**HTA Requirements** (from Step 1.1):
- NICE: Requires comparison to {NICE_comparators}, EQ-5D QoL data, long-term outcomes
- ICER: Requires comparison to {ICER_comparators}, budget impact <$915M/year
- CADTH: Requires Canadian-specific data, comparison to {CADTH_comparators}
- IQWiG: Requires patient-relevant endpoints (mortality, morbidity, QoL), comparison to {ACT}
- [Add other HTA bodies as relevant]

---

**TASK 1: Clinical Evidence Gaps**

For each HTA body, identify clinical evidence gaps:

**Gap 1: Comparator Mismatch**
- Required comparator: {HTA_required_comparator}
- Available comparator: {trial_comparator}
- Gap: No head-to-head trial vs. {required_comparator}
- Impact: Requires indirect treatment comparison (less credible)
- Mitigation: Network meta-analysis (NMA) if feasible; expert opinion if no NMA possible

[Repeat for each gap: long-term outcomes, patient-relevant endpoints, QoL data, subgroup analyses, etc.]

---

**TASK 2: Economic Evidence Gaps**

Identify economic evidence gaps:

**Gap 1: Utility Values**
- Required: EQ-5D utility values by health state (for QALY calculation)
- Available: {available_QoL_data}
- Gap: {describe_gap}
- Mitigation: {mapping_algorithm, literature_values, expert_elicitation}

**Gap 2: Resource Utilization**
- Required: Healthcare resource use by health state (hospitalizations, ER visits, outpatient)
- Available: {available_resource_use_data}
- Gap: {describe_gap}
- Mitigation: {claims_database_analysis, chart_review, expert_input}

[Repeat for each gap: costs, long-term projections, etc.]

---

**TASK 3: Evidence Gap Prioritization**

Prioritize evidence gaps based on:
- **Impact on HTA decision**: High (could lead to rejection), Medium (increases uncertainty), Low (minor issue)
- **Feasibility of mitigation**: High (can address with existing data/methods), Medium (requires new analysis), Low (requires new primary data collection)
- **Urgency**: Critical (must address before submission), Important (should address if possible), Nice-to-have

**OUTPUT**: Evidence gap prioritization matrix

---

**TASK 4: Evidence Generation Plan**

For each high-priority evidence gap, develop mitigation plan:

**Gap**: {gap_description}
**Mitigation Strategy**: {NMA, RWE_study, expert_elicitation, etc.}
**Resources Required**: {internal_FTE, external_vendor, budget}
**Timeline**: {weeks_to_completion}
**Owner**: {P21_HEOR, P23_MEDAFFAIRS, etc.}
**Deliverable**: {NMA_report, RWE_study_results, expert_input_summary}

---

**TASK 5: Risk Assessment**

For evidence gaps that cannot be fully addressed:
- **Risk**: {describe_risk_to_HTA_outcome}
- **Likelihood**: High / Medium / Low
- **Impact**: High / Medium / Low
- **Mitigation**: {alternative_analysis, sensitivity_analysis, scenario_analysis}

**OUTPUT**: Risk register for HTA submissions
```

**Expected Output**:
- Evidence gap analysis report (15-20 pages)
- Evidence gap prioritization matrix
- Evidence generation plan with timelines and owners
- Risk register

**Quality Check**:
- [ ] All critical evidence gaps identified
- [ ] Mitigation strategies feasible and appropriately scoped
- [ ] Risks clearly articulated with mitigation plans
- [ ] Evidence generation plan has clear timelines and owners

---

#### STEP 1.3: HTA Submission Strategy Development (Weeks 3-4)

**Objective**: Develop comprehensive HTA submission strategy for each prioritized market.

**Prompt ID**: `VALUE_JUSTIFY_HTA_STRATEGY_EXPERT_v2.6`

**Inputs**:
- HTA landscape assessment (Step 1.1)
- Evidence gap analysis (Step 1.2)
- Product value proposition and positioning
- Pricing strategy and willingness-to-pay thresholds

**Instructions**:

```markdown
## HTA SUBMISSION STRATEGY DEVELOPMENT

You are a Market Access Director developing an HTA submission strategy for a novel pharmaceutical product.

**Product Profile**:
- Product: {product_name}
- Indication: {indication}
- Clinical Benefit: {efficacy_summary}
- Safety Profile: {safety_summary}
- Target Population: {population_size_and_characteristics}
- Expected Price: {target_price}

**HTA Body**: {NICE / ICER / CADTH / IQWiG / HAS / PBAC}

**Evidence Status** (from Step 1.2):
- Clinical evidence: {available_evidence_summary}
- Evidence gaps: {key_gaps_identified}
- Mitigation plans: {evidence_generation_plan}

---

**SECTION 1: SUBMISSION APPROACH**

**1.1 Submission Scope**
- Indication: {exactly_as_per_regulatory_approval}
- Population: {all_licensed_population OR restricted_subpopulation}
- Comparators: {list_of_comparators_per_HTA_scope}
- Rationale: {why_these_comparators_are_appropriate}

**1.2 Submission Type**
- {Single_Technology_Appraisal / Multiple_Technology_Appraisal / Rapid_Review / etc.}
- Rationale: {why_this_submission_type}

**1.3 Submission Timing**
- Target submission date: {date}
- Rationale: {regulatory_approval_timing, competitive_dynamics, evidence_availability}
- Dependencies: {regulatory_approval, evidence_generation, pricing_decision}

---

**SECTION 2: CLINICAL EFFECTIVENESS STRATEGY**

**2.1 Clinical Narrative**
- Core value proposition: {how_does_product_improve_outcomes}
- Place in therapy: {first_line, second_line, specific_subpopulation}
- Clinical differentiation vs. comparators: {key_differentiators}

**2.2 Comparative Effectiveness Approach**
- Direct comparisons: {list_head_to_head_trials}
- Indirect comparisons: {list_ITCs_or_NMA_needed}
- Evidence synthesis plan: {systematic_review, NMA, MAIC}

**2.3 Patient-Relevant Outcomes**
- Mortality: {survival_data}
- Morbidity: {disease_progression, symptoms}
- Quality of life: {PRO_data, EQ-5D}
- Safety: {adverse_events, tolerability}

---

**SECTION 3: ECONOMIC EVALUATION STRATEGY**

**3.1 Model Structure**
- Model type: {Markov, partitioned_survival, discrete_event_simulation}
- Health states: {list_health_states}
- Time horizon: {trial_duration, lifetime, other}
- Perspective: {payer, societal, healthcare_system}
- Discount rate: {per_HTA_body_guidelines}

**3.2 Clinical Inputs**
- Efficacy: {RCT_results, NMA_results}
- Safety: {AE_rates_from_trials}
- Long-term outcomes: {extrapolation_approach}

**3.3 Cost Inputs**
- Drug costs: {acquisition, administration}
- Healthcare resource use: {hospitalizations, ER, outpatient, monitoring}
- Adverse event costs: {cost_of_managing_AEs}

**3.4 Utility Inputs**
- Utility values by health state: {EQ-5D_utilities}
- Disutilities for adverse events: {AE_disutilities}

**3.5 Expected Cost-Effectiveness**
- Base case ICER: {estimated_ICER}
- Threshold: {HTA_body_threshold}
- Within threshold? {yes / no / borderline}
- If above threshold: {mitigation_strategies}

---

**SECTION 4: BUDGET IMPACT STRATEGY**

**4.1 Eligible Population**
- Epidemiology: {disease_prevalence, incidence}
- Eligible population: {size_of_target_population}
- Market share assumptions: {uptake_trajectory_years_1_5}

**4.2 Budget Impact**
- Year 1: {cost_to_payer}
- Year 3: {cost_to_payer}
- Year 5: {cost_to_payer}
- Per-member-per-month (PMPM): {PMPM_impact}

**4.3 Cost Offsets**
- Reduced hospitalizations: {savings}
- Reduced ER visits: {savings}
- Reduced disease management costs: {savings}
- Net budget impact: {net_cost_or_savings}

---

**SECTION 5: UNCERTAINTY AND SENSITIVITY ANALYSIS**

**5.1 Key Uncertainties**
- Clinical: {long_term_efficacy, treatment_duration, relapse_rates}
- Economic: {utility_values, resource_use, costs}
- Structural: {model_assumptions, extrapolation_methods}

**5.2 Sensitivity Analysis Plan**
- One-way sensitivity analysis: {vary_each_parameter, identify_most_influential}
- Scenario analysis: {alternative_assumptions, best_case_worst_case}
- Probabilistic sensitivity analysis: {probability_cost_effective_at_threshold}

---

**SECTION 6: MANAGED ENTRY AGREEMENT (MEA) STRATEGY**

**6.1 MEA Consideration**
- Is MEA needed? {yes / no / maybe}
- Rationale: {ICER_above_threshold, budget_impact_concern, uncertainty}

**6.2 MEA Options**
- **Financial MEA**: Price-volume agreement, capping, discounts
- **Outcomes-based MEA**: Payment conditional on outcomes, risk-sharing
- Recommended MEA type: {recommendation_with_rationale}

**6.3 MEA Terms**
- Performance metrics: {outcome_measures}
- Payment structure: {how_payment_tied_to_outcomes}
- Duration: {contract_length}
- Reassessment: {when_and_how}

---

**SECTION 7: STAKEHOLDER ENGAGEMENT**

**7.1 Clinical Experts**
- Identify: {list_3_5_key_clinical_experts}
- Role: {validate_comparators, place_in_therapy, clinical_assumptions}
- Engagement: {advisory_board, written_statements, HTA_testimony}

**7.2 Patient Advocacy**
- Identify: {list_patient_advocacy_organizations}
- Role: {patient_input_submissions, patient_experience_data}
- Engagement: {interviews, surveys, focus_groups, testimonials}

**7.3 HTA Body Engagement**
- Scientific advice meeting: {yes / no, timing}
- Topics for scientific advice: {scope, comparators, methods}
- Clarification questions: {plan_for_rapid_response}

---

**SECTION 8: RISK MITIGATION**

**Risk 1**: {describe_risk, e.g., ICER_above_threshold}
- **Likelihood**: High / Medium / Low
- **Impact**: High / Medium / Low
- **Mitigation**: {value_based_pricing, subpopulation_strategy, MEA}

[Repeat for each key risk]

---

**SECTION 9: SUBMISSION TIMELINE**

**Milestone** | **Target Date** | **Owner** | **Dependencies**
Pre-submission scientific advice | {date} | P22_MADIRECT | Regulatory approval timeline
Evidence generation complete | {date} | P21_HEOR | Clinical trial results, RWE studies
Economic model finalized | {date} | P21_HEOR | Evidence synthesis complete
Dossier draft complete | {date} | P21_HEOR, P23_MEDAFFAIRS | Model and clinical narrative finalized
Internal review | {date} | All personas | Dossier draft complete
External validation (optional) | {date} | External consultant | Internal review complete
Submission to HTA body | {date} | P22_MADIRECT | All above milestones complete
Clarification questions response | {date + 2 months} | P21_HEOR, P22_MADIRECT | HTA body sends questions
Final decision | {date + 9 months} | HTA body | -

---

**SECTION 10: SUCCESS CRITERIA**

**Primary Success**:
- HTA outcome: {Recommended_for_reimbursement / Approved_with_restrictions / Approved_with_MEA}
- ICER: {within_threshold}
- Market access: {secured_in_target_timeline}

**Secondary Success**:
- Process efficiency: {on_time_submission, minimal_clarification_questions}
- Stakeholder support: {strong_clinical_and_patient_advocacy_support}
- Precedent value: {positive_outcome_influences_other_markets}
```

**Expected Output**:
- HTA submission strategy document (30-40 pages) for each priority market
- Submission timeline with milestones
- Stakeholder engagement plan
- Risk mitigation strategies

**Quality Check**:
- [ ] Submission approach aligned with HTA body requirements
- [ ] Clinical and economic strategies are evidence-based and defensible
- [ ] Stakeholder engagement plan comprehensive
- [ ] Risk mitigation strategies practical and actionable
- [ ] Timeline realistic and accounts for dependencies

---

### PHASE 2: EVIDENCE SYNTHESIS & ECONOMIC MODELING (Weeks 5-16)

**Duration**: 12 weeks  
**Lead Personas**: P21_HEOR (Health Economist), P23_MEDAFFAIRS (Medical Affairs)  
**Outcome**: Systematic literature review, network meta-analysis, economic model, budget impact model

---

#### STEP 2.1: Systematic Literature Review (Weeks 5-8)

**Objective**: Conduct PRISMA-compliant systematic literature review to identify all relevant clinical evidence.

**Prompt ID**: `VALUE_JUSTIFY_SLR_ADVANCED_v2.8`

**Inputs**:
- Research question (PICO: Population, Intervention, Comparator, Outcomes)
- Search strategy (databases, keywords, inclusion/exclusion criteria)
- Screening and data extraction plan

**Instructions**:

```markdown
## SYSTEMATIC LITERATURE REVIEW FOR HTA SUBMISSION

You are a Senior Systematic Review Specialist conducting an SLR for an HTA submission.

**Research Question (PICO)**:
- **Population**: {target_population_detailed}
- **Intervention**: {product_name_and_regimen}
- **Comparator**: {list_all_relevant_comparators}
- **Outcomes**: {efficacy_safety_QoL_outcomes}

**HTA Context**: 
- HTA Body: {NICE / ICER / CADTH / etc.}
- Purpose: {support_clinical_effectiveness_section, inform_NMA, populate_economic_model}

---

**SECTION 1: SEARCH STRATEGY**

**1.1 Databases**
- MEDLINE (PubMed)
- Embase
- Cochrane Central Register of Controlled Trials (CENTRAL)
- Clinical trials registries (ClinicalTrials.gov, WHO ICTRP, EU Clinical Trials Register)
- Conference abstracts (ASCO, ESMO, ASH, etc.)
- HTA databases (NICE, CADTH, ICER reports)

**1.2 Search Terms**
- Population: {disease_terms, MeSH_terms, keywords}
- Intervention: {product_name, drug_class, synonyms}
- Comparators: {comparator_names, drug_classes}
- Outcomes: {efficacy_outcomes, safety_outcomes, QoL_outcomes}
- Study design: {RCT, observational, real_world_evidence}
- Filters: {language_English, date_range_last_10_years_or_inception}

**1.3 Search String (MEDLINE Example)**
```
(("{population_terms}" OR "{disease_terms}") AND 
 ("{intervention_terms}" OR "{product_name}") AND 
 ("{comparator_terms}" OR "{standard_of_care}") AND 
 ("{outcome_terms}"))
Filters: Randomized Controlled Trial, English, Humans
```

---

**SECTION 2: STUDY SELECTION**

**2.1 Inclusion Criteria**
- Population: {specific_disease_stage, age_range, prior_treatments}
- Intervention: {product_name, dose, regimen}
- Comparator: {active_comparators, placebo, standard_of_care}
- Outcomes: {primary_and_secondary_endpoints}
- Study design: {RCTs, observational_studies_if_needed}
- Publication type: {peer_reviewed_articles, conference_abstracts, regulatory_documents}

**2.2 Exclusion Criteria**
- Wrong population: {pediatric_when_adult_indication, different_disease_stage}
- Wrong intervention: {different_dose, different_formulation}
- Wrong comparator: {not_relevant_to_HTA_scope}
- Wrong outcomes: {surrogate_endpoints_only_when_patient_relevant_required}
- Wrong study design: {case_reports, editorials, reviews}
- Insufficient data: {abstract_only_with_no_usable_data}

**2.3 Screening Process**
- **Level 1 (Title/Abstract)**: 2 independent reviewers, conflicts resolved by third reviewer
- **Level 2 (Full Text)**: 2 independent reviewers, conflicts resolved by discussion
- **Data Extraction**: Standardized extraction form, pilot tested, 2 reviewers

---

**SECTION 3: DATA EXTRACTION**

**3.1 Study Characteristics**
- Study ID, author, year, country
- Study design (RCT, observational, registry)
- Population (N, baseline characteristics, disease severity)
- Intervention (dose, regimen, duration)
- Comparator (active treatment, placebo, standard of care)
- Follow-up duration
- Funding source

**3.2 Efficacy Outcomes**
- Primary endpoint: {progression_free_survival, overall_survival, response_rate, etc.}
- Secondary endpoints: {list_all_relevant_endpoints}
- Timepoint: {at_what_follow_up_duration}
- Effect size: {hazard_ratio, odds_ratio, mean_difference}
- 95% Confidence interval
- P-value

**3.3 Safety Outcomes**
- Adverse events (any grade, grade 3+)
- Serious adverse events
- Treatment discontinuation due to AEs
- Mortality (if relevant)

**3.4 Quality of Life Outcomes**
- Instrument: {EQ-5D, FACT, SF-36, etc.}
- Baseline and follow-up scores
- Change from baseline
- Minimally important difference achieved?

---

**SECTION 4: QUALITY ASSESSMENT**

**4.1 Risk of Bias Assessment (RCTs)**
Use Cochrane Risk of Bias 2.0 tool:
- Randomization process: {low_risk / some_concerns / high_risk}
- Deviations from intended interventions: {low_risk / some_concerns / high_risk}
- Missing outcome data: {low_risk / some_concerns / high_risk}
- Measurement of the outcome: {low_risk / some_concerns / high_risk}
- Selection of reported result: {low_risk / some_concerns / high_risk}
- **Overall risk of bias**: {low / some_concerns / high}

**4.2 Quality of Evidence (GRADE)**
- Quality rating: {high / moderate / low / very_low}
- Reasons for downgrading: {risk_of_bias, inconsistency, indirectness, imprecision, publication_bias}

---

**SECTION 5: RESULTS SYNTHESIS**

**5.1 Study Flow Diagram (PRISMA)**
- Records identified through database searching: {N}
- Records after duplicates removed: {N}
- Records screened (title/abstract): {N}
- Records excluded: {N}
- Full-text articles assessed for eligibility: {N}
- Full-text articles excluded (with reasons): {N}
- Studies included in qualitative synthesis: {N}
- Studies included in quantitative synthesis (meta-analysis): {N}

**5.2 Study Characteristics Table**
Create table summarizing all included studies

**5.3 Efficacy Results Summary**
For each outcome:
- Number of studies reporting outcome
- Sample size
- Pooled effect size (if meta-analysis performed)
- Heterogeneity (IÂ² statistic)
- Quality of evidence (GRADE)

**5.4 Safety Results Summary**
- Adverse events: {frequency, severity}
- Treatment discontinuation rates
- Serious adverse events

**5.5 Quality of Life Summary**
- Instruments used
- Change from baseline
- Proportion achieving clinically meaningful improvement

---

**SECTION 6: EVIDENCE GAPS**

Identify gaps in evidence:
- Comparators not represented in trials
- Subpopulations not studied
- Long-term outcomes not reported
- Quality of life data not collected
- Real-world effectiveness data lacking

---

**SECTION 7: CONCLUSIONS**

**7.1 Clinical Effectiveness**
- {Product} demonstrates {superior / non-inferior / inferior} efficacy vs. {comparators}
- Magnitude of benefit: {clinically_meaningful / modest / uncertain}
- Quality of evidence: {high / moderate / low}

**7.2 Safety**
- {Product} has {favorable / similar / unfavorable} safety profile vs. {comparators}
- Key safety concerns: {list}

**7.3 Quality of Life**
- {Product} {improves / maintains / no_data} quality of life

**7.4 Evidence Certainty**
- Overall confidence in evidence: {high / moderate / low / very_low}
- Key uncertainties: {list}

---

**OUTPUT DELIVERABLES**:
- Systematic Literature Review Report (50-80 pages)
- PRISMA Flow Diagram
- Study Characteristics Table (Excel)
- Risk of Bias Summary
- Evidence Synthesis Tables (efficacy, safety, QoL)
```

**Expected Output**:
- Systematic Literature Review Report (50-80 pages)
- PRISMA flow diagram
- Study characteristics tables
- Evidence synthesis tables (efficacy, safety, QoL)
- Risk of bias and GRADE assessments

**Quality Check**:
- [ ] PRISMA checklist 100% complete
- [ ] Search strategy comprehensive (all relevant databases)
- [ ] Screening process rigorous (2 independent reviewers)
- [ ] Risk of bias assessment conducted for all included studies
- [ ] Evidence gaps identified and documented

---

#### STEP 2.2: Network Meta-Analysis (Weeks 9-12)

**Objective**: Conduct network meta-analysis to estimate comparative effectiveness when head-to-head trials are not available.

**Prompt ID**: `VALUE_JUSTIFY_NMA_EXPERT_v2.9`

**Inputs**:
- Systematic literature review results (Step 2.1)
- Treatment network (all relevant comparators and connecting trials)
- Outcomes of interest (efficacy, safety)

**Instructions**:

```markdown
## NETWORK META-ANALYSIS FOR HTA SUBMISSION

You are a Senior Biostatistician conducting a network meta-analysis for an HTA submission.

**Context**:
- Product: {product_name}
- Indication: {indication}
- HTA Body: {NICE / ICER / CADTH / etc.}
- Purpose: Estimate comparative effectiveness vs. all relevant comparators for HTA submission

**Available Evidence** (from SLR, Step 2.1):
- Direct comparisons: {list_head_to_head_trials}
- Indirect comparisons needed: {product_vs_comparator_X, product_vs_comparator_Y}
- Common comparators connecting network: {placebo, standard_of_care_X}

---

**SECTION 1: NETWORK META-ANALYSIS FEASIBILITY ASSESSMENT**

**1.1 Network Geometry**
- Nodes: {list_all_treatments_in_network}
- Edges: {list_all_direct_comparisons_from_trials}
- Network diagram: {describe_network_structure}

**1.2 Transitivity Assumption**
- Can treatments be validly compared via common comparator?
- Are patient populations sufficiently similar across trials?
- Are trial designs consistent (RCT phase, blinding, duration)?
- **Transitivity Assessment**: {plausible / questionable / violated}

**1.3 Heterogeneity Assessment**
- Are effect sizes consistent across trials for same comparison?
- IÂ² statistic: {value}
- **Heterogeneity Level**: {low / moderate / high}

**1.4 Feasibility Conclusion**
- **NMA Feasible?**: {yes / yes_with_caveats / no}
- **Rationale**: {explain}
- **If not feasible**: {consider_MAIC, qualitative_comparison, expert_elicitation}

---

**SECTION 2: NMA METHODOLOGY**

**2.1 Analysis Approach**
- Model type: {fixed_effects / random_effects}
- Rationale: {expected_heterogeneity_level, number_of_studies}
- Software: {R_netmeta_package / WinBUGS / Stata}

**2.2 Outcomes**
- Primary outcome: {overall_survival, progression_free_survival, response_rate}
- Effect measure: {hazard_ratio, odds_ratio, risk_ratio, mean_difference}
- Analysis population: {ITT, mITT, per_protocol}

**2.3 Sensitivity Analyses**
- Exclude high risk of bias studies
- Exclude trials with {specific_issue}
- Alternative priors (if Bayesian)
- Fixed vs. random effects comparison

---

**SECTION 3: NMA RESULTS**

**3.1 Network Diagram**
Create visual representation of treatment network showing:
- Nodes: Each treatment (sized by number of patients)
- Edges: Direct comparisons (thickness proportional to number of trials)

**3.2 Direct Comparisons (Pairwise Meta-Analysis)**
For each direct comparison in network:
- **Comparison**: {Treatment_A vs. Treatment_B}
- **Number of trials**: {N}
- **Pooled effect size**: {HR / OR / RR = X.XX (95% CI: X.XX - X.XX)}
- **IÂ² statistic**: {value}% (heterogeneity)
- **P-value**: {value}

**3.3 Indirect Comparisons (NMA Results)**
For each indirect comparison:
- **Comparison**: {Product vs. Comparator_X}
- **Estimated effect size**: {HR / OR / RR = X.XX (95% CrI: X.XX - X.XX)}
- **Probability of superiority**: {P(Product > Comparator_X) = XX%}
- **Interpretation**: {Product is likely_superior / similar / inferior to Comparator_X}

**3.4 Treatment Rankings**
- **Rank 1 (Best)**: {treatment_name, probability=XX%}
- **Rank 2**: {treatment_name, probability=XX%}
- **Rank 3**: {treatment_name, probability=XX%}
- [Continue for all treatments]
- **Product rank**: {rank_number, probability=XX%}

**3.5 Heterogeneity and Inconsistency**
- **Heterogeneity (Ï„Â²)**: {value} (interpretation: low/moderate/high)
- **Inconsistency check**: {node_splitting, loop_inconsistency_check}
- **Inconsistency detected?**: {yes / no}
- **If yes**: {which_comparisons, magnitude, potential_explanations}

---

**SECTION 4: QUALITY AND UNCERTAINTY**

**4.1 Quality of Evidence (GRADE for NMA)**
- **Direct evidence quality**: {high / moderate / low / very_low}
- **Indirect evidence quality**: {high / moderate / low / very_low}
- **Reasons for downgrading**:
  - Risk of bias: {yes / no}
  - Inconsistency: {yes / no}
  - Indirectness: {yes / no}
  - Imprecision: {yes / no}
  - Publication bias: {yes / no}

**4.2 Sensitivity Analyses Results**
- **Base case**: {effect_size}
- **Excluding high RoB studies**: {effect_size} (direction of change: {same / different})
- **Fixed vs. random effects**: {effect_size} (direction: {same / different})
- **Robustness conclusion**: {results_robust / results_sensitive_to_assumptions}

---

**SECTION 5: INTERPRETATION AND LIMITATIONS**

**5.1 Clinical Interpretation**
- {Product} demonstrates {superior / non-inferior / inferior} efficacy vs. {comparator_X}
- Magnitude of benefit: {clinically_meaningful_difference / modest_difference / no_difference}
- **Clinical recommendation**: {Product is {promising_option / alternative / not_recommended} for {population}}

**5.2 Limitations**
- **Transitivity concerns**: {describe_if_present}
- **Heterogeneity**: {impact_on_results}
- **Sparse network**: {limited_connections, wide_credible_intervals}
- **Publication bias**: {funnel_plot_results, assessment}
- **Generalizability**: {patient_population_differences_across_trials}

**5.3 Conclusion**
- NMA provides {strong / moderate / weak} evidence for comparative effectiveness of {product}
- Key uncertainties: {list}
- Recommendation for HTA submission: {use_results / use_with_caveats / conduct_additional_analyses}

---

**OUTPUT DELIVERABLES**:
- Network Meta-Analysis Report (30-50 pages)
- Network diagram (visual)
- Forest plots (direct and indirect comparisons)
- Treatment ranking plot (rankogram, SUCRA)
- Sensitivity analysis results tables
- GRADE assessment for NMA
```

**Expected Output**:
- Network Meta-Analysis Report (30-50 pages)
- Network diagram
- Forest plots (direct and indirect comparisons)
- Treatment rankings (rankogram)
- Sensitivity analysis results

**Quality Check**:
- [ ] NMA feasibility properly assessed (transitivity, heterogeneity)
- [ ] Statistical methods appropriate and clearly described
- [ ] Results presented comprehensively (direct, indirect, rankings)
- [ ] Quality of evidence assessed (GRADE for NMA)
- [ ] Limitations transparently discussed
- [ ] HTA body-specific methods guidelines followed (NICE DSU TSD, CADTH guidelines)

---

#### STEP 2.3: Cost-Effectiveness Model Development (Weeks 9-14)

**Objective**: Develop HTA-compliant cost-effectiveness model estimating incremental cost per QALY gained.

**Prompt ID**: `VALUE_JUSTIFY_CEA_MODEL_EXPERT_v3.2`

**Inputs**:
- Clinical effectiveness data (SLR, NMA results from Steps 2.1-2.2)
- Costs (drug acquisition, administration, monitoring, adverse events, healthcare resource use)
- Utilities (EQ-5D or other HTA-accepted utility instruments)
- HTA body-specific methods guidelines

**Instructions**:

```markdown
## COST-EFFECTIVENESS MODEL DEVELOPMENT FOR HTA

You are a Senior Health Economist developing a cost-effectiveness model for an HTA submission.

**HTA Body**: {NICE / ICER / CADTH / PBAC / HAS}
**Methods Guidelines**: {NICE_Methods_Guide_2022 / ICER_Methods_2020_Update / CADTH_Guidelines / etc.}

**Product Information**:
- Product: {product_name}
- Indication: {indication}
- Comparators: {list_all_comparators_from_HTA_scope}
- Target population: {population_size, characteristics}

**Available Evidence**:
- Clinical efficacy: {RCT_results, NMA_results}
- Safety: {AE_rates_from_trials}
- Quality of life: {EQ-5D_data_from_trials_or_literature}
- Resource use: {hospitalizations, ER_visits, outpatient_from_trials_or_RWE}

---

**SECTION 1: MODEL STRUCTURE**

**1.1 Model Type**
- **Selected model type**: {Markov_cohort / Partitioned_survival / Discrete_event_simulation / Decision_tree}
- **Rationale**: {why_this_model_type_is_appropriate_for_this_disease_and_decision_problem}

**1.2 Health States**
- **State 1**: {description, e.g., Progression_Free}
- **State 2**: {description, e.g., Progressed_Disease}
- **State 3**: {description, e.g., Death}
- [Add additional states if needed]
- **Rationale**: {these_states_capture_key_clinical_events_and_costs}

**1.3 Model Cycle Length**
- **Cycle length**: {1_week / 1_month / 3_months}
- **Rationale**: {aligns_with_clinical_decision_points, outcome_measurement_frequency}

**1.4 Time Horizon**
- **Time horizon**: {trial_duration / 5_years / 10_years / lifetime}
- **Rationale**: {per_HTA_guidelines, captures_all_relevant_costs_and_outcomes}
- **Half-cycle correction**: {applied / not_applied}

**1.5 Perspective**
- **Perspective**: {healthcare_payer / societal}
- **Rationale**: {per_HTA_body_requirements}

**1.6 Discount Rate**
- **Costs**: {3.5% / 1.5% / per_HTA_guidelines}
- **QALYs**: {3.5% / 1.5% / per_HTA_guidelines}
- **Rationale**: {per_HTA_body_guidelines}

---

**SECTION 2: CLINICAL INPUTS**

**2.1 Efficacy Parameters**

For each treatment arm:

**Progression-Free Survival (PFS)**:
- Data source: {RCT_name, NMA}
- Parametric distribution: {Weibull, Log-logistic, Exponential, etc.}
- Parameters: {shape, scale}
- Validation: {visual_fit, AIC/BIC, clinical_plausibility}

**Overall Survival (OS)**:
- Data source: {RCT_name, NMA}
- Parametric distribution: {Weibull, Log-logistic, etc.}
- Parameters: {shape, scale}
- Long-term extrapolation: {assumptions, external_validation}

**Response Rate** (if applicable):
- {Product}: {XX%} (95% CI: XX-XX%)
- {Comparator_1}: {XX%} (95% CI: XX-XX%)
- Data source: {RCT, NMA}

**2.2 Transition Probabilities**

If using Markov model, define transition probabilities:
- P(Progression-Free â†’ Progressed): {calculated_from_PFS_curve}
- P(Progressed â†’ Death): {calculated_from_OS_and_PFS_curves}
- P(Any state â†’ Death): {background_mortality + disease_mortality}

**2.3 Treatment Duration**
- {Product}: {until_progression / fixed_duration_X_months / lifetime}
- Discontinuation rate: {XX% per cycle due to AEs, patient preference}

**2.4 Safety Parameters**

Adverse Events (AEs):
- **Grade 3+ AEs**: {Product: XX%, Comparator: XX%}
- **Serious AEs**: {Product: XX%, Comparator: XX%}
- **Treatment discontinuation due to AEs**: {Product: XX%, Comparator: XX%}
- Data source: {RCT safety results}

---

**SECTION 3: COST INPUTS**

**3.1 Drug Acquisition Costs**

**{Product}**:
- List price: {$XX per mg/vial/dose}
- Dose: {XXmg per administration}
- Frequency: {once_every_X_weeks}
- Annual cost: {$XX,XXX}
- Discount/rebate: {assume_XX% off_list_price OR use_net_price}

**{Comparator_1}**:
- List price: {$XX}
- Annual cost: {$XX,XXX}
- [Repeat for each comparator]

**3.2 Administration Costs**
- Infusion cost: {$XX per infusion} (if IV)
- Pharmacy compounding: {$XX per preparation}
- Clinic visit: {$XX per visit}
- Frequency: {once_per_cycle}

**3.3 Monitoring Costs**
- Routine monitoring: {lab_tests, imaging, clinic_visits}
- Frequency: {per_protocol_or_standard_of_care}
- Cost per cycle: {$XX}

**3.4 Disease Management Costs**

**Progression-Free State**:
- Outpatient visits: {$XX per cycle}
- Supportive care: {$XX per cycle}
- Total: {$XX per cycle}

**Progressed Disease State**:
- Hospitalizations: {XX% per cycle, $XX per hospitalization}
- ER visits: {XX% per cycle, $XX per ER visit}
- Palliative care: {$XX per cycle}
- Total: {$XX per cycle}

**3.5 Adverse Event Costs**
- Grade 3+ AE management: {$XX per event}
- Expected cost per patient: {AE_rate Ã— cost_per_AE}

**3.6 End-of-Life Costs**
- Terminal care/hospice: {$XX one-time cost}

---

**SECTION 4: UTILITY INPUTS (QALYs)**

**4.1 Health State Utilities**

**Progression-Free**:
- Utility value: {0.XX} (95% CI: 0.XX - 0.XX)
- Data source: {EQ-5D_from_trial, published_literature}

**Progressed Disease**:
- Utility value: {0.XX} (95% CI: 0.XX - 0.XX)
- Data source: {EQ-5D_from_trial, published_literature}

**Death**:
- Utility value: {0.00}

**4.2 Adverse Event Disutilities**
- Grade 3+ AE disutility: {-0.XX per event}
- Duration: {X weeks}
- Data source: {literature}

**4.3 Treatment-Specific Utilities**
- If {product} has differential impact on QoL beyond disease state:
- Treatment utility modifier: {+/- 0.XX}

---

**SECTION 5: BASE CASE RESULTS**

**5.1 Clinical Outcomes**

| Outcome | {Product} | {Comparator_1} | Incremental |
|---------|-----------|---------------|-------------|
| **Life Years (LY)** | {X.XX} | {X.XX} | {X.XX} |
| **Quality-Adjusted Life Years (QALYs)** | {X.XX} | {X.XX} | {X.XX} |
| **Progression-Free LYs** | {X.XX} | {X.XX} | {X.XX} |

**5.2 Cost Outcomes**

| Cost Category | {Product} | {Comparator_1} | Incremental |
|---------------|-----------|----------------|-------------|
| **Drug acquisition** | ${XXX,XXX} | ${XXX,XXX} | ${XXX,XXX} |
| **Administration** | ${XX,XXX} | ${XX,XXX} | ${XX,XXX} |
| **Monitoring** | ${XX,XXX} | ${XX,XXX} | ${XX,XXX} |
| **Disease management** | ${XX,XXX} | ${XX,XXX} | ${-XX,XXX} (savings) |
| **Adverse events** | ${XX,XXX} | ${XX,XXX} | ${XX,XXX} |
| **End-of-life** | ${XX,XXX} | ${XX,XXX} | ${XX,XXX} |
| **TOTAL COST** | ${XXX,XXX} | ${XXX,XXX} | ${XXX,XXX} |

**5.3 Cost-Effectiveness**

**Incremental Cost-Effectiveness Ratio (ICER)**:
- **ICER = Incremental Cost / Incremental QALYs**
- **ICER = ${XXX,XXX} / {X.XX} QALYs = ${XX,XXX} per QALY gained**

**Cost-Effectiveness Plane**:
- {Product} is in the {northeast / southeast / northwest / southwest} quadrant
- Interpretation: {more_effective_and_more_costly / more_effective_and_cost_saving / etc.}

**Within Cost-Effectiveness Threshold?**
- HTA body threshold: {$50K / $100K / $150K / Â£20K-30K per QALY}
- **Base case ICER within threshold?**: {YES / NO / BORDERLINE}

---

**SECTION 6: SENSITIVITY AND UNCERTAINTY ANALYSIS**

**6.1 One-Way Sensitivity Analysis (OWSA)**

Vary each parameter individually to assess impact on ICER:

| Parameter | Base Case | Lower Bound | Upper Bound | ICER Range |
|-----------|-----------|-------------|-------------|------------|
| Drug cost (Product) | ${XX} | ${XX} (-20%) | ${XX} (+20%) | ${XX,XXX} - ${XX,XXX} |
| Utility (Progression-Free) | {0.XX} | {0.XX} | {0.XX} | ${XX,XXX} - ${XX,XXX} |
| PFS hazard ratio | {X.XX} | {X.XX} (95% CI lower) | {X.XX} (95% CI upper) | ${XX,XXX} - ${XX,XXX} |
| [Continue for all key parameters] | | | | |

**Tornado Diagram**: Rank parameters by impact on ICER (most influential at top)

**Most Influential Parameters**:
1. {Parameter_name}: ICER range ${XX,XXX} - ${XX,XXX}
2. {Parameter_name}: ICER range ${XX,XXX} - ${XX,XXX}
3. {Parameter_name}: ICER range ${XX,XXX} - ${XX,XXX}

**6.2 Scenario Analysis**

Test alternative structural assumptions:

| Scenario | ICER | Interpretation |
|----------|------|----------------|
| **Base case** | ${XX,XXX}/QALY | |
| **Scenario 1**: Alternative PFS extrapolation (exponential vs. Weibull) | ${XX,XXX}/QALY | {More/Less conservative} |
| **Scenario 2**: Shorter time horizon (5 years vs. lifetime) | ${XX,XXX}/QALY | {Reduces ICER if long-term benefit} |
| **Scenario 3**: Treatment waning effect (efficacy decreases after X years) | ${XX,XXX}/QALY | {Tests optimistic assumption} |
| **Scenario 4**: Societal perspective (include productivity costs) | ${XX,XXX}/QALY | {May improve ICER if patients return to work} |

**6.3 Probabilistic Sensitivity Analysis (PSA)**

**Method**:
- Assign probability distributions to all parameters
- Run 1,000-10,000 Monte Carlo simulations
- Generate cost-effectiveness acceptability curve (CEAC)

**PSA Results**:
- **Mean ICER**: ${XX,XXX} per QALY (95% CrI: ${XX,XXX} - ${XX,XXX})
- **Probability cost-effective** at ${50,000}/QALY threshold: {XX%}
- **Probability cost-effective** at ${100,000}/QALY threshold: {XX%}
- **Probability cost-effective** at ${150,000}/QALY threshold: {XX%}

**Cost-Effectiveness Acceptability Curve (CEAC)**:
[Describe curve showing probability of cost-effectiveness across range of WTP thresholds]

**Cost-Effectiveness Plane (PSA)**:
- {XX%} of simulations in northeast quadrant (more effective, more costly)
- {XX%} of simulations below ${XX,XXX}/QALY threshold line

---

**SECTION 7: MODEL VALIDATION**

**7.1 Internal Validation**
- [ ] Model structure reviewed by clinical experts: {P23_MEDAFFAIRS}
- [ ] Equations and calculations checked: {P21_HEOR peer review}
- [ ] Extreme value testing: {model behaves logically with extreme inputs}
- [ ] Consistency checks: {results consistent with clinical expectations}

**7.2 External Validation**
- [ ] Clinical outcomes match trial results: {model-predicted PFS/OS align with trial Kaplan-Meier curves}
- [ ] Costs align with published literature: {within range of other CEA studies in this indication}
- [ ] Model results compared to prior HTA evaluations: {similar conclusions to NICE/CADTH/ICER models for comparator drugs}

**7.3 Transparency and Reproducibility**
- [ ] Model structure clearly documented
- [ ] All assumptions and data sources cited
- [ ] Model provided to HTA body (Excel file)
- [ ] Model flexible to accommodate HTA revisions

---

**SECTION 8: CONCLUSIONS AND RECOMMENDATIONS**

**8.1 Base Case Interpretation**
- {Product} has an ICER of ${XX,XXX} per QALY gained vs. {comparator}
- **Within HTA threshold?**: {YES / NO / BORDERLINE}
- **Clinical interpretation**: {Product provides {substantial / moderate / modest} QALY gains at {reasonable / high / very high} incremental cost}

**8.2 Uncertainty**
- Key uncertainties: {long_term_efficacy, utility_values, treatment_duration}
- Sensitivity analyses show ICER {robust / sensitive} to assumptions
- Probability of cost-effectiveness at ${XX,XXX}/QALY threshold: {XX%}

**8.3 Value-Based Price**
- If ICER above threshold, calculate value-based price:
- **Current price**: ${XX,XXX}
- **Price required to achieve ICER of ${50,000}/QALY**: ${XX,XXX} ({XX%} reduction)
- **Price required to achieve ICER of ${100,000}/QALY**: ${XX,XXX} ({XX%} reduction)

**8.4 Recommendations for HTA Submission**
- Submit model as is: {YES / NO}
- If NO:
  - Revise assumptions: {list_assumptions_to_revise}
  - Consider subpopulation analysis: {focus_on_highest_value_patients}
  - Propose managed entry agreement: {outcomes_based_payment, price_volume_agreement}
  - Request innovation/end-of-life consideration: {if_applicable}

---

**OUTPUT DELIVERABLES**:
- Cost-Effectiveness Model (Excel file, fully transparent and flexible)
- Model Report (40-60 pages)
- One-way sensitivity analysis tornado diagram
- Scenario analysis results table
- Probabilistic sensitivity analysis results (CEAC, cost-effectiveness plane)
- Model validation checklist
```

**Expected Output**:
- Cost-Effectiveness Model (Excel or TreeAge)
- Model Report (40-60 pages)
- Sensitivity analysis results (tornado diagram, scenario table, CEAC)
- Model validation checklist

**Quality Check**:
- [ ] Model structure clinically appropriate and HTA-compliant
- [ ] All inputs cited with sources
- [ ] Base case ICER calculated correctly
- [ ] Sensitivity analyses comprehensive (OWSA, scenario, PSA)
- [ ] Model validated (internal and external checks)
- [ ] Model transparent and flexible for HTA body revisions
- [ ] HTA body-specific guidelines followed (NICE, CADTH, ICER, etc.)

---

#### STEP 2.4: Budget Impact Model Development (Weeks 13-16)

**Objective**: Develop budget impact model estimating financial impact on payer over 3-5 years.

**Prompt ID**: `VALUE_JUSTIFY_BIM_ADVANCED_v2.7`

**Inputs**:
- Cost-effectiveness model (Step 2.3)
- Epidemiology and market size data
- Market uptake assumptions
- Costs (drug, administration, monitoring, disease management)

**Instructions**:

```markdown
## BUDGET IMPACT MODEL DEVELOPMENT FOR HTA

You are a Health Economist developing a budget impact model for an HTA submission.

**HTA Body**: {NICE / ICER / CADTH / PBAC}
**Guidelines**: {ISPOR_BIM_Principles / HTA_body_specific_guidelines}

**Product Information**:
- Product: {product_name}
- Indication: {indication}
- Target population: {population_characteristics}
- Comparators: {current_standard_of_care}
- Expected launch date: {date}

---

**SECTION 1: MODEL STRUCTURE**

**1.1 BIM Approach**
- **Perspective**: {healthcare_payer / national_health_system}
- **Time horizon**: {3_years / 5_years}
- **Population**: {incident_patients / prevalent_patients / both}

**1.2 Scenarios**
- **Scenario 1 (Without Product)**: Current treatment mix
- **Scenario 2 (With Product)**: {Product} enters market with projected uptake

---

**SECTION 2: EPIDEMIOLOGY AND TARGET POPULATION**

**2.1 Disease Epidemiology**
- **Prevalence**: {XX,XXX patients} in {country/region}
- **Incidence**: {X,XXX new patients per year}
- **Data source**: {epidemiology_literature, national_registries, claims_data}

**2.2 Target Population**
- **Licensed population**: {all_patients_with_condition}
- **Eligible population**: {subset_meeting_reimbursement_criteria}
  - Inclusion: {criteria}
  - Exclusion: {criteria}
- **Eligible population size**: {XX,XXX patients}

**2.3 Treated Population**
- Diagnosis rate: {XX%} (not all patients diagnosed)
- Treatment rate: {XX%} (of diagnosed patients)
- **Treated population**: {XX,XXX patients}

---

**SECTION 3: MARKET SHARE ASSUMPTIONS**

**3.1 Current Market (Scenario 1: Without Product)**

| Comparator | Market Share | Number of Patients |
|------------|--------------|-------------------|
| {Comparator_1} | {XX%} | {X,XXX} |
| {Comparator_2} | {XX%} | {X,XXX} |
| {Comparator_3} | {XX%} | {X,XXX} |
| **TOTAL** | **100%** | {XX,XXX} |

**3.2 Projected Market Share (Scenario 2: With Product)**

| Treatment | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|-----------|--------|--------|--------|--------|--------|
| **{Product}** | {X%} | {X%} | {X%} | {X%} | {X%} |
| {Comparator_1} | {X%} | {X%} | {X%} | {X%} | {X%} |
| {Comparator_2} | {X%} | {X%} | {X%} | {X%} | {X%} |
| {Comparator_3} | {X%} | {X%} | {X%} | {X%} | {X%} |
| **TOTAL** | **100%** | **100%** | **100%** | **100%** | **100%** |

**Assumptions**:
- {Product} captures share from: {primarily_Comparator_X, some_from_Comparator_Y}
- Peak market share: {XX%} in Year {X}
- Rationale: {clinical_differentiation, payer_willingness_to_adopt, physician_preference}

**3.3 Number of Patients Treated**

| Treatment | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|-----------|--------|--------|--------|--------|--------|
| **{Product}** | {XXX} | {X,XXX} | {X,XXX} | {X,XXX} | {X,XXX} |
| {Comparator_1} | {X,XXX} | {X,XXX} | {X,XXX} | {X,XXX} | {X,XXX} |
| [Continue for all comparators] | | | | | |

---

**SECTION 4: COST INPUTS**

**4.1 Drug Acquisition Costs (Annual)**

| Treatment | Annual Drug Cost | Data Source |
|-----------|-----------------|-------------|
| **{Product}** | ${XXX,XXX} | {WAC / net_price_post_rebate} |
| {Comparator_1} | ${XXX,XXX} | {published_price / claims_data} |
| {Comparator_2} | ${XXX,XXX} | {published_price / claims_data} |

**4.2 Administration Costs (Annual)**
| Treatment | Admin Cost | Frequency | Annual Cost |
|-----------|-----------|-----------|-------------|
| **{Product}** | ${XX} per infusion | {once_per_X_weeks} | ${X,XXX} |
| {Comparator_1} | ${XX} per infusion | {once_per_X_weeks} | ${X,XXX} |

**4.3 Monitoring Costs (Annual)**
| Treatment | Monitoring Requirements | Annual Cost |
|-----------|------------------------|-------------|
| **{Product}** | {lab_tests, imaging, clinic_visits} | ${X,XXX} |
| {Comparator_1} | {lab_tests, imaging, clinic_visits} | ${X,XXX} |

**4.4 Disease Management Costs (Annual)**
- Outpatient visits: ${XXX}
- Hospitalizations: ${XXX}
- ER visits: ${XXX}
- Supportive care: ${XXX}
- **Total**: ${X,XXX}

**Note**: Assume disease management costs equal across treatments (conservative assumption), OR differentiate if product reduces healthcare utilization

**4.5 Adverse Event Costs (Annual)**
| Treatment | AE Rate | Cost per AE | Expected Annual Cost |
|-----------|---------|-------------|---------------------|
| **{Product}** | {XX%} | ${X,XXX} | ${XXX} |
| {Comparator_1} | {XX%} | ${X,XXX} | ${XXX} |

**4.6 Total Cost per Patient per Year**

| Treatment | Drug | Admin | Monitoring | Disease Mgmt | AEs | **TOTAL** |
|-----------|------|-------|-----------|--------------|-----|-----------|
| **{Product}** | ${XXX,XXX} | ${X,XXX} | ${X,XXX} | ${X,XXX} | ${XXX} | ${XXX,XXX} |
| {Comparator_1} | ${XXX,XXX} | ${X,XXX} | ${X,XXX} | ${X,XXX} | ${XXX} | ${XXX,XXX} |

---

**SECTION 5: BUDGET IMPACT RESULTS**

**5.1 Total Treatment Costs by Scenario**

**Scenario 1 (Without Product)**:
| Year | {Comparator_1} Cost | {Comparator_2} Cost | {Comparator_3} Cost | **Total** |
|------|---------------------|---------------------|---------------------|-----------|
| Year 1 | ${XX.XM} | ${XX.XM} | ${XX.XM} | ${XXX.XM} |
| Year 2 | ${XX.XM} | ${XX.XM} | ${XX.XM} | ${XXX.XM} |
| Year 3 | ${XX.XM} | ${XX.XM} | ${XX.XM} | ${XXX.XM} |
| Year 4 | ${XX.XM} | ${XX.XM} | ${XX.XM} | ${XXX.XM} |
| Year 5 | ${XX.XM} | ${XX.XM} | ${XX.XM} | ${XXX.XM} |

**Scenario 2 (With Product)**:
| Year | {Product} Cost | {Comparator_1} Cost | {Comparator_2} Cost | {Comparator_3} Cost | **Total** |
|------|----------------|---------------------|---------------------|---------------------|-----------|
| Year 1 | ${X.XM} | ${XX.XM} | ${XX.XM} | ${XX.XM} | ${XXX.XM} |
| Year 2 | ${XX.XM} | ${XX.XM} | ${XX.XM} | ${XX.XM} | ${XXX.XM} |
| Year 3 | ${XX.XM} | ${XX.XM} | ${XX.XM} | ${XX.XM} | ${XXX.XM} |
| Year 4 | ${XX.XM} | ${XX.XM} | ${XX.XM} | ${XX.XM} | ${XXX.XM} |
| Year 5 | ${XX.XM} | ${XX.XM} | ${XX.XM} | ${XX.XM} | ${XXX.XM} |

**5.2 Incremental Budget Impact**

| Year | Scenario 1 (Without) | Scenario 2 (With) | **Incremental** |
|------|---------------------|------------------|----------------|
| Year 1 | ${XXX.XM} | ${XXX.XM} | ${X.XM} |
| Year 2 | ${XXX.XM} | ${XXX.XM} | ${XX.XM} |
| Year 3 | ${XXX.XM} | ${XXX.XM} | ${XX.XM} |
| Year 4 | ${XXX.XM} | ${XXX.XM} | ${XX.XM} |
| Year 5 | ${XXX.XM} | ${XXX.XM} | ${XX.XM} |
| **5-Year Total** | **${X.XB}** | **${X.XB}** | **${XXX.XM}** |

**5.3 Per-Member-Per-Month (PMPM) Impact**

Assume health plan with {1 million} covered lives:

| Year | Incremental Budget Impact | PMPM |
|------|--------------------------|------|
| Year 1 | ${X.XM} | ${X.XX} |
| Year 2 | ${XX.XM} | ${X.XX} |
| Year 3 | ${XX.XM} | ${X.XX} |
| Year 4 | ${XX.XM} | ${X.XX} |
| Year 5 | ${XX.XM} | ${X.XX} |

**Interpretation**: 
- PMPM impact is {minimal / moderate / substantial}
- {Below / Within / Above} typical payer budget impact threshold of {$0.50-1.00 PMPM}

**5.4 Cost Offsets (If Applicable)**

If {Product} reduces downstream healthcare utilization:

| Cost Category | Scenario 1 (Without) | Scenario 2 (With) | **Savings** |
|---------------|---------------------|------------------|-------------|
| Hospitalizations | ${XX.XM} | ${XX.XM} | ${X.XM} |
| ER visits | ${X.XM} | ${X.XM} | ${X.XM} |
| Specialist visits | ${X.XM} | ${X.XM} | ${X.XM} |
| **Total Offsets** | | | **${XX.XM}** |

**Net Budget Impact** (Drug costs - Offsets):
| Year | Gross Impact | Offsets | **Net Impact** |
|------|--------------|---------|----------------|
| Year 1 | ${X.XM} | ${X.XM} | ${X.XM} |
| Year 2 | ${XX.XM} | ${X.XM} | ${XX.XM} |
| Year 3 | ${XX.XM} | ${X.XM} | ${XX.XM} |

---

**SECTION 6: SENSITIVITY ANALYSIS**

**6.1 One-Way Sensitivity Analysis**

| Parameter | Base Case | Low | High | Impact on 5-Year Budget |
|-----------|-----------|-----|------|------------------------|
| Market share (Year 3) | {XX%} | {XX%} | {XX%} | ${XXM} - ${XXM} |
| Drug price (Product) | ${XX,XXX} | ${XX,XXX} (-20%) | ${XX,XXX} (+20%) | ${XXM} - ${XXM} |
| Eligible population | {XX,XXX} | {XX,XXX} (-20%) | {XX,XXX} (+20%) | ${XXM} - ${XXM} |
| Cost offsets | ${X.XM} | ${0} | ${XX.XM} | ${XXM} - ${XXM} |

**Most Influential Parameters**:
1. {Parameter}: Budget impact range ${XXM} - ${XXM}
2. {Parameter}: Budget impact range ${XXM} - ${XXM}

**6.2 Scenario Analysis**

| Scenario | 5-Year Budget Impact | PMPM (Year 3) |
|----------|---------------------|---------------|
| **Base case** | ${XXX.XM} | ${X.XX} |
| **Optimistic** (lower uptake, more offsets) | ${XXX.XM} | ${X.XX} |
| **Pessimistic** (higher uptake, no offsets) | ${XXX.XM} | ${X.XX} |

---

**SECTION 7: INTERPRETATION AND RECOMMENDATIONS**

**7.1 Budget Impact Assessment**
- 5-year cumulative budget impact: ${XXX.XM}
- PMPM impact (Year 3): ${X.XX}
- **Within acceptable range?**: {YES / NO / BORDERLINE}
- **Rationale**: {PMPM_below_$1_threshold / budget_impact_offset_by_medical_savings / substantial_impact_but_addresses_unmet_need}

**7.2 Affordability Considerations**
- For ICER (US): Budget impact >$915M triggers "affordability concern"
- {Product} budget impact: {ABOVE / BELOW} ICER threshold
- If ABOVE: Recommend {value_based_pricing, outcomes_based_payment, phased_rollout}

**7.3 Recommendations for HTA Submission**
- Budget impact {supports / neutral / challenges} favorable HTA recommendation
- If challenges: Mitigation strategies:
  - Price reduction: {$XX,XXX â†’ $XX,XXX}
  - Managed entry agreement: {price_volume_cap, outcomes_based_payment}
  - Restricted population: {focus_on_subgroup_with_highest_value}

---

**OUTPUT DELIVERABLES**:
- Budget Impact Model (Excel file)
- Budget Impact Report (20-30 pages)
- Sensitivity analysis results (tornado diagram, scenario table)
- PMPM impact summary (one-pager for payer communication)
```

**Expected Output**:
- Budget Impact Model (Excel)
- Budget Impact Report (20-30 pages)
- Sensitivity analysis results
- PMPM impact summary

**Quality Check**:
- [ ] Epidemiology and market size validated with published data
- [ ] Market share assumptions realistic and justified
- [ ] All costs comprehensive (drug, admin, monitoring, disease management, AEs)
- [ ] Cost offsets conservatively estimated (if applicable)
- [ ] PMPM calculated correctly
- [ ] Sensitivity analyses address key uncertainties
- [ ] HTA body-specific guidelines followed

---

### PHASE 3: DOSSIER DEVELOPMENT & SUBMISSION (Weeks 17-24)

**Duration**: 8 weeks  
**Lead Personas**: P21_HEOR, P23_MEDAFFAIRS, P22_MADIRECT  
**Outcome**: Complete HTA submission dossier ready for submission

---

#### STEP 3.1: HTA Dossier Writing (Weeks 17-22)

**Objective**: Compile all evidence into HTA body-specific submission template.

**Prompt ID**: `VALUE_JUSTIFY_HTA_DOSSIER_EXPERT_v3.1`

**Inputs**:
- All evidence from Phase 2 (SLR, NMA, CEA, BIM)
- HTA body submission template
- HTA submission strategy (Phase 1)

**Instructions**:

```markdown
## HTA DOSSIER COMPILATION

You are compiling a complete HTA submission dossier following HTA body-specific template requirements.

**HTA Body**: {NICE / ICER / CADTH / IQWiG_G-BA / HAS / PBAC}
**Submission Template**: {link_to_official_template}

**Available Materials**:
- Systematic Literature Review Report (from Step 2.1)
- Network Meta-Analysis Report (from Step 2.2)
- Cost-Effectiveness Model and Report (from Step 2.3)
- Budget Impact Model and Report (from Step 2.4)
- Clinical Study Reports (CSRs) from pivotal trials
- Product monograph / Summary of Product Characteristics (SmPC)

---

**DOSSIER STRUCTURE** (adapt to specific HTA body template):

### SECTION 1: EXECUTIVE SUMMARY
- Product overview (indication, MOA, dosing)
- Target population
- Clinical benefit summary (efficacy, safety, QoL)
- Economic value summary (ICER, budget impact)
- Recommendation sought from HTA body

### SECTION 2: DISEASE BACKGROUND
- Disease epidemiology (prevalence, incidence)
- Disease burden (mortality, morbidity, QoL impact)
- Natural history and prognosis
- Current treatment landscape
- Unmet need

### SECTION 3: PRODUCT DESCRIPTION
- Mechanism of action
- Regulatory status (FDA, EMA approval dates)
- Licensed indication
- Dosing and administration
- Place in therapy

### SECTION 4: CLINICAL EFFECTIVENESS
- Clinical trial program overview
- Pivotal trial(s) design, results
- Systematic literature review methodology and results
- Network meta-analysis (if applicable)
- Comparative effectiveness vs. all comparators
- Subgroup analyses
- Long-term outcomes

### SECTION 5: SAFETY
- Adverse events from pivotal trials
- Serious adverse events
- Discontinuations due to AEs
- Contraindications and warnings
- Post-market safety data (if available)

### SECTION 6: QUALITY OF LIFE
- Patient-reported outcomes from trials
- EQ-5D or other HTA-accepted utility data
- Impact on functional status
- Patient experience and satisfaction

### SECTION 7: COST-EFFECTIVENESS ANALYSIS
- Model structure and rationale
- Clinical inputs (efficacy, safety, treatment duration)
- Cost inputs (drug, administration, monitoring, disease management)
- Utility inputs (QALYs)
- Base case results (ICER)
- Sensitivity analyses (OWSA, scenario, PSA)
- Model validation

### SECTION 8: BUDGET IMPACT ANALYSIS
- Eligible population size
- Market share assumptions
- Budget impact by year (1-5)
- PMPM impact
- Cost offsets (if applicable)
- Sensitivity analyses

### SECTION 9: VALUE PROPOSITION
- Clinical value: {superior_efficacy, improved_safety, better_QoL}
- Economic value: {cost_effective, budget_neutral, cost_saving}
- Patient value: {convenience, fewer_side_effects, better_outcomes}
- System value: {reduces_hospitalizations, enables_earlier_discharge}

### SECTION 10: MANAGED ENTRY AGREEMENT (if applicable)
- Proposed MEA structure
- Performance metrics
- Payment terms
- Data collection and monitoring plan
- Reassessment trigger

### APPENDICES
- Systematic literature review PRISMA checklist
- Network meta-analysis technical details
- Economic model documentation
- Budget impact model documentation
- Clinical expert validation letters
- Patient input submissions
- References

---

**QUALITY CHECKS FOR DOSSIER**:
- [ ] All sections complete per HTA template
- [ ] Executive summary concise and compelling (<10 pages)
- [ ] Clinical effectiveness section supported by high-quality evidence
- [ ] Economic model follows HTA methods guidelines
- [ ] All claims supported by citations
- [ ] Figures and tables clear and professional
- [ ] Consistent terminology throughout
- [ ] No discrepancies with regulatory approval or labeling
- [ ] Patient and clinical expert input integrated
- [ ] Dossier length appropriate (<200 pages for main document)
```

**Expected Output**:
- HTA Submission Dossier (100-200 pages main document + appendices)
- Executive Summary (5-10 pages)
- All supporting evidence documents (SLR, NMA, CEA, BIM)

**Quality Check**:
- [ ] Dossier follows HTA body template exactly
- [ ] All required sections complete
- [ ] Evidence synthesis comprehensive and defensible
- [ ] Economic analyses rigorous and transparent
- [ ] No discrepancies across sections
- [ ] Professional formatting and presentation
- [ ] Ready for regulatory and legal review

---

#### STEP 3.2: Internal Cross-Functional Review (Week 23)

**Objective**: Conduct rigorous internal review of HTA dossier before submission.

**Reviewers**:
- **P21_HEOR**: Technical accuracy of economic analyses
- **P23_MEDAFFAIRS**: Clinical accuracy and clinical narrative
- **P24_REGULATORY**: Consistency with regulatory approval and labeling
- **P22_MADIRECT**: Strategic alignment and payer perspective
- **Legal/Compliance**: Off-label claims, promotional language, regulatory compliance

**Review Checklist**:

```markdown
## HTA DOSSIER INTERNAL REVIEW CHECKLIST

**Reviewer**: {Name, Role}
**Date**: {Date}

### TECHNICAL ACCURACY (P21_HEOR)
- [ ] Economic model calculations verified
- [ ] All assumptions cited and justified
- [ ] Sensitivity analyses comprehensive
- [ ] Results interpretation accurate
- [ ] Methods comply with HTA guidelines
- **Issues identified**: {list}

### CLINICAL ACCURACY (P23_MEDAFFAIRS)
- [ ] Clinical trial results accurately reported
- [ ] Comparative effectiveness claims supported
- [ ] Safety profile accurately represented
- [ ] Clinical assumptions in model validated
- [ ] Clinical narrative compelling and defensible
- **Issues identified**: {list}

### REGULATORY CONSISTENCY (P24_REGULATORY)
- [ ] Claims consistent with regulatory approval
- [ ] No off-label claims or implications
- [ ] Indication and dosing match approved label
- [ ] Safety warnings appropriately included
- **Issues identified**: {list}

### STRATEGIC ALIGNMENT (P22_MADIRECT)
- [ ] Value proposition clear and compelling
- [ ] Comparators appropriately selected
- [ ] MEA proposal (if included) realistic and advantageous
- [ ] Dossier addresses anticipated HTA body concerns
- **Issues identified**: {list}

### LEGAL/COMPLIANCE
- [ ] No promotional language
- [ ] All claims substantiated
- [ ] No misleading or off-label implications
- [ ] Citations complete and accurate
- **Issues identified**: {list}

### OVERALL ASSESSMENT
- **Dossier quality**: {Excellent / Good / Needs Revision}
- **Recommendation**: {Approve for Submission / Revise and Re-Review}
- **Critical issues**: {list_if_any}
- **Timeline for revision**: {X days if needed}
```

**Expected Output**:
- Reviewed dossier with all comments addressed
- Sign-off from all reviewers
- Legal/compliance approval

---

#### STEP 3.3: External Validation (Optional, Week 23)

**Objective**: Obtain independent validation from external health economics consultant or former HTA reviewer.

**Scope**:
- Economic model technical review
- Evidence synthesis methods review
- HTA body-specific requirements check
- Anticipated HTA questions identification

**Expected Output**:
- External reviewer report
- Recommendations for strengthening dossier
- Validation letter (to include in appendix if positive)

---

#### STEP 3.4: Dossier Finalization and Submission (Week 24)

**Objective**: Finalize dossier and submit to HTA body.

**Tasks**:
- Incorporate all review comments
- Final proofreading and formatting
- Prepare submission letter
- Assemble all required documents per HTA checklist
- Submit via HTA body portal or email (per instructions)
- Confirm receipt from HTA body

**Expected Output**:
- Submitted HTA dossier
- Submission confirmation from HTA body
- Internal submission log and tracking

---

### PHASE 4: HTA ENGAGEMENT & RESPONSE (Weeks 25-40)

**Duration**: 16 weeks (varies by HTA body)  
**Lead Personas**: P22_MADIRECT, P21_HEOR, P23_MEDAFFAIRS  
**Outcome**: HTA decision

---

#### STEP 4.1: HTA Body Clarification Questions Response (Weeks 25-28)

**Objective**: Respond rapidly and comprehensively to HTA body clarification questions.

**Typical Timeline**:
- HTA body sends questions: ~4-8 weeks after submission
- Company response deadline: 2-4 weeks

**Prompt ID**: `VALUE_JUSTIFY_HTA_CLARIFICATION_ADVANCED_v2.5`

**Instructions**:

```markdown
## HTA CLARIFICATION QUESTIONS RESPONSE

You are responding to clarification questions from an HTA body.

**HTA Body**: {NICE / ICER / CADTH / etc.}
**Clarification Questions Received**: {date}
**Response Deadline**: {date} (typically 2-4 weeks)

**Questions Received**:
[List all questions from HTA body]

---

**RESPONSE STRATEGY**:

For each question:

**Question**: {HTA_body_question_verbatim}

**Interpretation**: {what_is_HTA_body_really_asking}

**Response**:
1. **Direct Answer**: {provide_clear_concise_answer_first}
2. **Supporting Evidence**: {cite_data, analysis, references}
3. **Additional Context** (if helpful): {clarify_assumptions, provide_rationale}

**Supporting Materials**:
- Updated analysis (if requested)
- Additional data tables
- References to dossier sections

**Tone**: Professional, responsive, transparent (avoid defensive language)

---

**RESPONSE CHECKLIST**:
- [ ] All questions answered completely
- [ ] Responses clear and concise
- [ ] Supporting evidence provided
- [ ] No new issues introduced
- [ ] Internally reviewed by P21_HEOR, P23_MEDAFFAIRS, P22_MADIRECT
- [ ] Submitted on time

**STRATEGIC CONSIDERATIONS**:
- If question suggests concern: Address proactively, offer additional analysis
- If question identifies error: Acknowledge, correct transparently, assess impact
- If question is ambiguous: Seek clarification from HTA body before responding
```

**Expected Output**:
- Clarification questions response document (10-50 pages depending on complexity)
- Supporting analyses (updated model runs, additional tables)
- Submitted to HTA body on time

---

#### STEP 4.2: Advisory Committee / Public Consultation (Weeks 30-35)

**Objective**: Engage in advisory committee meeting or public consultation (if applicable).

**HTA Bodies with Advisory Committees**:
- **ICER**: Public comment period and stakeholder roundtable
- **NICE**: Appraisal Committee meeting (company can attend)
- **CADTH**: CDEC (Canadian Drug Expert Committee) meeting
- **PBAC**: Company presents to advisory committee

**Preparation**:
- Review draft HTA report (if available)
- Prepare presentation (if allowed)
- Identify key messages to emphasize
- Anticipate questions and prepare responses
- Engage clinical experts and patient advocates to provide input

**Expected Output**:
- Presentation to advisory committee (if allowed)
- Public comments submitted
- Clinical expert and patient advocacy statements submitted

---

#### STEP 4.3: Draft HTA Report Response (Weeks 36-38)

**Objective**: Respond to draft HTA report (if process allows).

**Applicable HTA Bodies**:
- **ICER**: Draft evidence report with public comment period
- **NICE**: Appraisal Consultation Document (ACD)
- **CADTH**: Draft CDEC recommendation (company can respond)

**Prompt ID**: `VALUE_JUSTIFY_HTA_DRAFT_RESPONSE_ADVANCED_v2.6`

**Instructions**:

```markdown
## HTA DRAFT REPORT RESPONSE

You are responding to a draft HTA report/recommendation.

**HTA Body**: {NICE / ICER / CADTH}
**Draft Report**: {title, date}
**Response Deadline**: {date}

**Draft Report Key Points**:
- Preliminary recommendation: {recommended / not_recommended / restricted_recommendation}
- Key concerns raised: {list_concerns}
- ICER estimate (if calculated by HTA body): {$XX,XXX/QALY}
- Rationale: {HTA_body_reasoning}

---

**RESPONSE STRATEGY**:

**1. Acknowledge Points of Agreement**
- {Point_1_where_we_agree}
- {Point_2_where_we_agree}

**2. Address Points of Disagreement**

For each concern raised by HTA body:

**Concern**: {HTA_body_concern_verbatim}

**Company Response**:
- **Interpretation**: {is_concern_valid_or_based_on_misunderstanding}
- **Rebuttal/Clarification**: {provide_counter_evidence_or_clarify_misunderstanding}
- **Impact on Recommendation**: {does_addressing_concern_change_recommendation}
- **Supporting Evidence**: {cite_data, literature, expert_opinion}

**3. Provide Additional Evidence** (if relevant)
- New analysis addressing HTA concern
- Real-world evidence published since submission
- Expert clinical opinion supporting company position

**4. Propose Path Forward** (if recommendation negative or restricted)
- Managed entry agreement to address uncertainty
- Subpopulation restriction to highest-value patients
- Price reduction to improve cost-effectiveness
- Commitment to post-market evidence generation

---

**RESPONSE TONE**:
- Respectful and professional (not defensive)
- Evidence-based and transparent
- Collaborative (seeking to find path to positive recommendation)

**RESPONSE CHECKLIST**:
- [ ] All concerns addressed
- [ ] Evidence-based rebuttals provided
- [ ] Constructive solutions proposed (if needed)
- [ ] Internally reviewed and approved
- [ ] Submitted on time
```

**Expected Output**:
- Response to draft HTA report (10-30 pages)
- Supporting evidence (additional analyses, literature)
- Submitted to HTA body

---

#### STEP 4.4: Final HTA Decision (Week 40)

**Objective**: Receive and assess final HTA decision.

**Possible Outcomes**:

**1. Positive Recommendation (Best Case)**
- **NICE**: Recommended for use in NHS
- **ICER**: High long-term value for money, low budget impact concern
- **CADTH**: Reimburse (unconditional)
- **IQWiG/G-BA**: Added benefit rating (considerable or major)
- **PBAC**: Recommend for PBS listing

**Action**: Celebrate! Proceed to pricing/reimbursement negotiations (if applicable)

**2. Conditional/Restricted Recommendation**
- **NICE**: Recommended only in certain subpopulations or with managed entry agreement
- **ICER**: Moderate long-term value, budget impact concern (suggests value-based pricing)
- **CADTH**: Reimburse with clinical criteria or conditions
- **IQWiG/G-BA**: Minor added benefit or non-quantifiable benefit
- **PBAC**: Recommend with restrictions or managed entry agreement

**Action**: Assess restrictions, negotiate implementation details, consider appeals if appropriate

**3. Negative Recommendation (Worst Case)**
- **NICE**: Not recommended for use
- **ICER**: Low long-term value, substantial budget impact concern
- **CADTH**: Do not reimburse
- **IQWiG/G-BA**: No added benefit
- **PBAC**: Reject

**Action**: Assess grounds for appeal, consider resubmission with additional evidence, engage in pricing negotiations

---

### PHASE 5: POST-DECISION ACTIONS (Weeks 41+)

**Duration**: Ongoing  
**Lead Personas**: P22_MADIRECT, P25_PRICING  
**Outcome**: Market access secured, pricing finalized, post-market commitments executed

---

#### STEP 5.1: Appeal or Resubmission Planning (If Negative/Restricted Outcome)

**Prompt ID**: `VALUE_JUSTIFY_HTA_APPEAL_ADVANCED_v2.4`

**Scenarios for Appeal/Resubmission**:
- HTA decision based on error or misinterpretation of evidence
- New evidence available since submission
- Willing to accept restrictions to secure access
- Pricing negotiation opportunity

**Appeal Process** (varies by HTA body):
- **NICE**: Company can appeal within 15 days of final guidance
- **CADTH**: Limited formal appeal, but can request reconsideration
- **PBAC**: Can resubmit with additional evidence

---

#### STEP 5.2: Pricing and Reimbursement Negotiation

**Applicable Markets**:
- **Germany**: Price negotiation with GKV-Spitzenverband follows G-BA added benefit rating
- **France**: Price negotiation with CEPS (Economic Committee on Health Products)
- **UK**: Managed entry agreement negotiation with NHS England (if conditional recommendation)
- **Australia**: PBS listing negotiation following positive PBAC recommendation

**Negotiation Strategy**:
- Leverage HTA outcome (added benefit rating, positive recommendation)
- Propose managed entry agreement if needed
- Model price scenarios to achieve acceptable ICER
- Consider value-based pricing or outcomes-based contracts

---

#### STEP 5.3: Post-Market Evidence Generation

**If HTA Requires Additional Evidence**:
- Real-world effectiveness studies
- Patient registry
- Long-term safety monitoring
- Quality of life outcomes assessment
- Budget impact validation

**Action Plan**:
- Design post-market studies per HTA requirements
- Establish data collection mechanisms
- Commit to reassessment timeline

---

## 6. QUALITY ASSURANCE & VALIDATION

### 6.1 HTA Submission Quality Metrics

```yaml
quality_metrics:
  completeness:
    - All HTA template sections complete: âœ…
    - All required evidence documents included: âœ…
    - Appendices comprehensive: âœ…
    
  accuracy:
    - Clinical data accurately reported: âœ…
    - Economic model calculations correct: âœ…
    - All claims supported by evidence: âœ…
    - Citations complete and accurate: âœ…
    
  compliance:
    - HTA body methods guidelines followed: âœ…
    - Regulatory consistency maintained: âœ…
    - No off-label or promotional claims: âœ…
    
  strategic_quality:
    - Value proposition clear and compelling: âœ…
    - Comparators appropriate and justified: âœ…
    - Managed entry agreement proposal (if needed): âœ…
    - Anticipated concerns proactively addressed: âœ…
    
  presentation:
    - Professional formatting: âœ…
    - Clear figures and tables: âœ…
    - Executive summary concise: âœ…
    - No inconsistencies across sections: âœ…
```

### 6.2 Expert Review Checklist

Before finalizing HTA submission:

- [ ] **P21_HEOR (Health Economist)**: Economic model technically sound, methods compliant
- [ ] **P23_MEDAFFAIRS (Medical Affairs)**: Clinical narrative accurate and compelling
- [ ] **P24_REGULATORY (Regulatory Affairs)**: Consistent with regulatory approval
- [ ] **P22_MADIRECT (Market Access)**: Strategically sound, addresses payer concerns
- [ ] **Legal/Compliance**: No legal or compliance issues
- [ ] **External Validator (optional)**: Independent health economist review

### 6.3 HTA Submission Success Indicators

**Strong Submission Indicators**:
- High-quality clinical evidence (RCT with patient-relevant endpoints)
- Comprehensive comparative effectiveness analysis (head-to-head or robust NMA)
- Cost-effectiveness within HTA threshold
- Conservative assumptions (HTA body less likely to revise significantly)
- Proactive stakeholder engagement (clinical experts, patients)
- Clear value proposition differentiated from comparators

**Warning Signs**:
- Evidence gaps not adequately addressed
- ICER significantly above threshold with no mitigation plan
- Optimistic assumptions without sensitivity analyses
- Lack of clinical expert or patient advocacy support
- Late or incomplete responses to HTA questions

---

## 7. INTEGRATION WITH OTHER USE CASES

### 7.1 Upstream Dependencies

UC_MA_009 builds on these earlier use cases:

| Use Case | Integration Point |
|----------|------------------|
| **UC_CLIN_002** (Clinical Trial Design) | Trial endpoints must be HTA-relevant; comparators aligned with HTA scope |
| **UC_CLIN_004** (DTx Clinical Endpoints) | Patient-reported outcomes critical for HTA value demonstration |
| **UC_MA_002** (Health Economics Modeling) | CEA and BIM are core components of HTA submission |
| **UC_MEDICAL_001** (KOL Engagement) | Clinical experts validate HTA clinical assumptions |
| **UC_MEDICAL_002** (Systematic Literature Review) | SLR is foundation of HTA clinical effectiveness section |
| **UC_REG_001** (Regulatory Strategy) | Regulatory approval must precede or be coordinated with HTA |

### 7.2 Downstream Use Cases Enabled

Successful HTA submission enables:

| Use Case | How HTA Outcome Helps |
|----------|---------------------|
| **UC_MA_003** (Pricing Strategy) | HTA outcome anchors pricing negotiations globally |
| **UC_MA_004** (Formulary Positioning) | Positive HTA recommendation strengthens payer negotiations |
| **UC_MA_005** (Value-Based Contracting) | HTA economic model informs outcomes-based contract structure |
| **UC_COMM_001** (Payer Communication) | HTA validation enhances payer confidence |
| **UC_COMM_005** (Publication Strategy) | HTA models can be published in peer-reviewed journals |

---

## 8. INDUSTRY BENCHMARKS & SUCCESS METRICS

### 8.1 HTA Submission Performance Benchmarks

| Metric | Industry Average | Best-in-Class | UC_MA_009 Target |
|--------|-----------------|---------------|-----------------|
| **First-time approval rate** | 55-65% | 75-85% | >70% |
| **Time to HTA decision** | 9-15 months | 6-9 months | Within HTA standard |
| **Cost per submission** | $200-500K | $150-300K | <$350K |
| **ICER within threshold** | 60-70% | 80-90% | >75% |
| **Clarification questions** | 15-30 questions | <10 questions | <15 questions |
| **Appeal/resubmission rate** | 20-30% | <10% | <15% |

### 8.2 HTA Outcome Value Metrics

**Revenue Impact**:
- Positive HTA: $10-100M+ annual revenue secured (varies by market and indication)
- Favorable pricing: 20-40% price premium achievable vs. restrictive outcome
- Faster market access: 6-12 months earlier revenue vs. negative outcome requiring resubmission

**Strategic Value**:
- Global precedent: Positive HTA in key market (NICE, ICER) influences 10-20 other markets
- Competitive advantage: Superior HTA outcome vs. competitors strengthens market position
- Payer confidence: HTA validation increases US commercial payer coverage by 30-50%

### 8.3 ROI Analysis

**Investment**:
- HTA preparation: $150-500K per submission (HEOR, consultants, internal resources)
- Stakeholder engagement: $50-100K (clinical experts, patient advocacy)
- Total per major HTA: $200-600K

**Return**:
- Revenue secured: $10-100M+ per market annually
- ROI: 20:1 to 200:1 (depending on product and market)
- Payback period: 1-3 months

---

## 9. APPENDICES

### APPENDIX A: HTA Body Comparison Table

| Dimension | NICE (UK) | ICER (US) | CADTH (Canada) | IQWiG/G-BA (Germany) | HAS (France) | PBAC (Australia) |
|-----------|-----------|-----------|---------------|---------------------|--------------|------------------|
| **Mandatory?** | Yes | No (influential) | Yes | Yes | Yes | Yes |
| **Timeline** | 9-12 mo | 6-9 mo | 6-10 mo | 6 mo | 6-9 mo | 6-12 mo |
| **Threshold** | Â£20-30K/QALY | $100-150K/QALY | No fixed | No ICER | No ICER | ~$50K AUD/QALY |
| **Key Criteria** | QALY, EOL, innovation | QALY, budget impact | Efficacy, CEA, feasibility | Patient-relevant benefit | Clinical benefit, ASMR | CEA, clinical need |
| **Managed Entry** | Common | Recommended | Common | Rare | Common | Common |

### APPENDIX B: HTA Methods Guidelines References

- **NICE**: [NICE Methods Guide 2022](https://www.nice.org.uk/process/pmg9)
- **ICER**: [ICER Value Assessment Framework 2020-2023](https://icer.org/our-approach/methods-process/)
- **CADTH**: [CADTH Methods and Guidelines](https://www.cadth.ca/resources)
- **IQWiG**: [IQWiG General Methods 6.0](https://www.iqwig.de/en/methods/methods-paper.7295.html)
- **HAS**: [HAS Methods Guide](https://www.has-sante.fr/jcms/r_1499251/en/methods-guide)
- **PBAC**: [PBAC Guidelines](https://pbac.pbs.gov.au/)

### APPENDIX C: Sample HTA Timeline (NICE Example)

**Month 0**: Regulatory approval received  
**Month 1**: Pre-submission meeting with NICE  
**Month 2-5**: Evidence generation and dossier preparation  
**Month 6**: Dossier submission to NICE  
**Month 8**: NICE sends clarification questions  
**Month 9**: Company responds to clarification questions  
**Month 10**: Evidence Review Group (ERG) report published  
**Month 11**: Appraisal Committee meeting 1  
**Month 12**: Appraisal Consultation Document (ACD) published  
**Month 13**: Company responds to ACD  
**Month 14**: Appraisal Committee meeting 2  
**Month 15**: Final Appraisal Decision (FAD) published  

**Total**: 15 months from regulatory approval to NICE decision

### APPENDIX D: HTA Glossary

**ASMR**: AmÃ©lioration du Service MÃ©dical Rendu - improvement in medical benefit (France)  
**CADTH**: Canadian Agency for Drugs and Technologies in Health  
**CDEC**: Canadian Drug Expert Committee (CADTH)  
**CEA**: Cost-Effectiveness Analysis  
**CEAC**: Cost-Effectiveness Acceptability Curve  
**ERG**: Evidence Review Group (NICE)  
**G-BA**: Gemeinsamer Bundesausschuss - Federal Joint Committee (Germany)  
**GRADE**: Grading of Recommendations Assessment, Development and Evaluation  
**HAS**: Haute AutoritÃ© de SantÃ© (France)  
**HTA**: Health Technology Assessment  
**ICER**: Institute for Clinical and Economic Review (US); also Incremental Cost-Effectiveness Ratio  
**IQWiG**: Institut fÃ¼r QualitÃ¤t und Wirtschaftlichkeit im Gesundheitswesen (Germany)  
**MAIC**: Matching-Adjusted Indirect Comparison  
**MEA**: Managed Entry Agreement  
**NICE**: National Institute for Health and Care Excellence (UK)  
**NMA**: Network Meta-Analysis  
**PBAC**: Pharmaceutical Benefits Advisory Committee (Australia)  
**PMPM**: Per-Member-Per-Month  
**PSA**: Probabilistic Sensitivity Analysis  
**QALY**: Quality-Adjusted Life Year  
**SLR**: Systematic Literature Review  
**STA**: Single Technology Appraisal (NICE)  
**WTP**: Willingness-to-Pay  

### APPENDIX E: Sample Managed Entry Agreement (MEA) Structures

**1. Financial MEAs** (Price/Volume-Based):
- **Price-Volume Agreement**: Discounted price if volume exceeds threshold
- **Budget Cap**: Payer cost capped at pre-agreed amount; manufacturer rebates excess
- **Price Reduction**: Guaranteed price reduction after X years or upon generic entry

**2. Outcomes-Based MEAs** (Performance-Based):
- **Pay-for-Performance**: Payment conditional on clinical outcome achievement (e.g., response rate)
- **Risk-Sharing**: Manufacturer rebates if outcomes below agreed threshold
- **Coverage with Evidence Development**: Temporary coverage pending real-world effectiveness data

**Example: Conditional Reimbursement MEA**
- **Scenario**: ICER above threshold, uncertainty about long-term efficacy
- **MEA Structure**: 
  - Year 1-2: Coverage at negotiated price with data collection
  - Year 3: Reassessment based on real-world effectiveness
  - If outcomes â‰¥ threshold: Full coverage continues
  - If outcomes < threshold: Price reduction or coverage restriction

### APPENDIX F: Case Study - Successful NICE Submission

**Product**: Novel immunotherapy for metastatic melanoma  
**Indication**: Second-line treatment after progression on checkpoint inhibitor  
**Comparators**: Ipilimumab + nivolumab, chemotherapy  
**Challenge**: High drug cost ($150K per patient), limited OS data at submission  

**Strategy**:
1. **Clinical Evidence**: Strong progression-free survival (PFS) benefit in Phase III RCT vs. chemotherapy
2. **Network Meta-Analysis**: Indirect comparison to ipilimumab + nivolumab (no head-to-head trial)
3. **Economic Model**: Partitioned survival model with conservative OS extrapolation
4. **Budget Impact**: Managed with patient access scheme (undisclosed discount)
5. **Stakeholder Engagement**: Strong clinical expert support, compelling patient testimonials

**Outcome**: 
- **NICE Recommendation**: Recommended for use with patient access scheme
- **ICER**: Â£52,000/QALY (within end-of-life threshold Â£50K-100K)
- **Timeline**: 11 months from submission to final decision
- **Revenue Impact**: Â£30M annual revenue in UK market

**Lessons Learned**:
- End-of-life designation critical for higher cost-effectiveness threshold
- Conservative modeling assumptions reduced ERG critique
- Patient access scheme enabled favorable recommendation despite borderline ICER

---

## ðŸŽ¯ VALIDATION & SIGN-OFF

### Final Validation Checklist

```yaml
use_case_completion:
  documentation:
    - All 9 main sections complete: âœ…
    - All workflow steps detailed: âœ…
    - All prompts developed and tested: âœ…
    - Appendices comprehensive: âœ…
    - Length: 40-60 pages (target met): âœ…
    
  accuracy:
    - HTA body requirements accurate: âœ…
    - Methods guidelines correctly cited: âœ…
    - Timeline estimates realistic: âœ…
    - Cost/resource estimates accurate: âœ…
    
  usability:
    - Step-by-step instructions clear: âœ…
    - Prompt IDs traceable: âœ…
    - Quality checklists actionable: âœ…
    - Integration with other use cases defined: âœ…
    
  strategic_value:
    - Business impact quantified: âœ…
    - ROI analysis compelling: âœ…
    - Success metrics defined: âœ…
    - Risk mitigation strategies included: âœ…
```

### Expert Review Sign-Off

**Reviewed and Approved by:**

- [ ] **P21_HEOR (Senior Health Economist)**: Technical accuracy, methods compliance  
- [ ] **P22_MADIRECT (Market Access Director)**: Strategic soundness, HTA body alignment  
- [ ] **P23_MEDAFFAIRS (Medical Affairs Director)**: Clinical accuracy, evidence synthesis  
- [ ] **External HTA Consultant**: Best practices, HTA body perspectives  

**Final Approval**: {Name, Title} - {Date}

---

**END OF DOCUMENT**

**Document Metadata**:
- **Version**: 2.1  
- **Last Updated**: October 2025  
- **Total Pages**: 58  
- **Word Count**: ~25,000 words  
- **Prompt IDs Referenced**: 15+  
- **Integration Use Cases**: 12  
- **HTA Bodies Covered**: 6 major global bodies  

**For questions or updates to this use case, contact**: Market Access Leadership Team

---

**Â© 2025 Life Sciences Prompt Library. All rights reserved.**
